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ABSTRACT 
 
A salient feature in the course of multiple sclerosis (MS) is myelin and axonal damage 
followed by oligodendrocyte degeneration. The current MS therapies are mainly focused 
on restricting inflammation by moderating the immune response, whereas the 
oligodendroglial preservation and regeneration have been poorly understood. It is long 
known that fibroblast growth factors (FGFs) and their receptors (FGFRs) play profound 
roles in neurons and oligodendrocyte proliferation, migration and differentiation as well as 
central nervous system (CNS) development. Yet, this study is the first to investigate the 
role of oligodendroglial FGFR2 in the pathology of experimental autoimmune 
encephalomyelitis (EAE) utilizing a conditional oligodendrocyte knockout mice. 
Concerning the various physiological and pathological roles attributed to FGFR2 
signaling, we hypothesized that EAE immunization will affect Fgfr2 knockout mice more 
severely.  Surprisingly, we observed a milder EAE disease course as well as a reduced 
inflammation, lymphocyte and macrophage infiltration, demyelination and axonal damage 
in oligodendroglial Fgfr2 knockout mice. Protein analysis showed a shift in FGFR2 
downstream signaling, leading to lower ERK phosphorylation and increased AKT 
phosphorylation in oligodendroglial Fgfr2 knockout mice. Moreover, we report that TrkB 
(the receptor for brain derived neurotrophic factor) was up-regulated in oligodendroglial 
Fgfr2 knockout mice which is known to induce neuroprotective and neuro-regenerative 
effects. These findings suggest a novel and not previously described role for 
oligodendroglial Fgfr2 in the course of EAE. 
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1 INTRODUCTION 
  
1.1 Multiple sclerosis  
Multiple sclerosis (MS) is the most common autoimmune inflammatory disorder affecting 
central nervous system (CNS) (Kieseier et al., 2005). The initial description of MS dates 
back to 14th century but it was Jean-Martin Charcot in 1868 (a French neurologist) who 
first described MS as a separate neurological condition (Compston, 1988, Kumar et al., 
2010). A century following Charcot’s discovery, the progress on understanding and 
treating MS has been very slow and only during the recent decades a meaningful forward 
momentum has been generated. Multiple sclerosis is a complex chronic inflammatory 
disease characterized by demyelination, oligodendrocyte and axonal injury (Hoglund and 
Maghazachi, 2014). The prevalence of MS is not uniform around the world, nor across 
the genders (female: male sex ratio ~ 3:1) (von Budingen et al., 2015). MS occurs more 
commonly in people living in the northern hemisphere (Caucasian root) and Europe is 
considered to be a high prevalence region for MS (defined by Kurtzke as a prevalence ≥ 
30/100,000) (Kingwell et al., 2013). According to the Multiple Sclerosis International 
Federation (MSIF) until June 2013, worldwide up to 2.3 million people were affected by 
MS.  
Figure 1. Prevalence of Multiple sclerosis. (Source: WHO MS Atlas) 
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1.1.1 Etiology 
Multiple sclerosis is a complex autoimmune disorder with its exact underlying pathology 
remained unclear. There are enough evidence associating MS pathogenesis to both 
genetic susceptibility and environmental factors (Figure 2). 
Genetic:  In a pure genetically controlled disorder, the occurrence rate of the condition is 
100% within the identical twins. In MS this ratio drops to 25 percent and even lower (3%) 
in siblings or children of patients with MS (Hoglund and Maghazachi, 2014). In recent 
years using genome wide association studies (GWAS) over 50 genes with MS risk factors 
were identified, most of which are associated with the immune system, including 
interleukin (IL)-2 and IL-7 (Gourraud et al., 2012). 
Environment: The exact environmental factors behind MS are not precisely discovered 
however, several environmental exposures are known to increase the risk of MS 
development. Epidemiology studies suggest involvement of viruses, particularly Epstein-
Barr virus (EBV), measles, and HTLV-1 in the pathogenesis of MS. (Gustavsen et al., 
2014). Low levels of sun exposure (vitamin D status), especially in early childhood, are 
also known to increase risk of MS (Aivo et al., 2015). Scientific investigations draw links 
between MS development and its progress with other lifestyle elements such as; smoking, 
obesity, vitamin A levels, exercise, alcohol consumption and so on (Fragoso, 2014).     
  
1.1.2 Symptoms and life quality of patients  
MS has highly variable clinical symptoms and progression patterns among patients while 
each individual’s symptoms could also change over time. These symptoms depend not 
only on the location of MS lesions but also on the slowed conduction properties displayed 
by affected axons (Newland et al., 2014). Different MS related symptoms include fatigue, 
pain, sleep disturbance, depression, anxiety, irritability, cognitive impairment, spasticity, 
ataxia,  and poor balance as well as MS generated symptom clusters (symptoms that are 
related to each other and occur together) such as functional walking capacity, and 
perceived health and illness intrusiveness (Figure 3) (Shahrbanian et al., 2015).  
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Figure 2. Different elements attributed in MS development (Image by J.Oksenberg/UCSF) 
Figure 3. The major symptoms of MS are shown in the image (Image by J.Oksenberg/UCSF) 
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The timing, pattern, and co-occurrence of symptoms may influence symptom recognition 
and adversely affect quality of life. Some symptoms interact to make each other worse, 
for example, pain and depression, social withdrawal due to fear of incontinence, 
sedentary lifestyle and in general a deteriorated quality of life might appear (Newland et 
al., 2014). Structural equation modelling (SEM) enables researchers to examine 
diagnostic overlap for MS and depression and the complex relationships between 
patients’ physical and mental health states (Gunzler et al., 2015). Multiple Sclerosis can 
also have a considerable influence on the individual’s sense of self. Physical changes 
and functional limitations may lead to a sense of loss of identity or role strain, especially 
when the individual can no longer perform previously valued activities (Pagnini et al., 
2014). People with MS struggle to continue working and a higher percentage of people 
with MS are unemployed compared to the rest of population. A Danish study found that 
the probability of remaining without an early pension 20 years after entry to the study was 
at 22% for people with MS while at 86% for non-MS controls (Sweetland et al., 2012).   
 
1.1.3 Diagnosis  
The initial MS diagnostic criteria were based on clinical features. The oldest of such 
criteria was Schumacher criteria which called for 2 separate clinical relapses in time and 
space while further specified signs and symptoms were missing Later Poser criteria 
added laboratory and paraclinical parameters for diagnosis with presence of oligoclonal 
bands  in the CSF (Poser et al., 1983). With the advance of new neurological techniques 
such as magnetic resonance imaging (MRI) the need for clinical evidence is replaced with 
radiological and chemical markers (McDonald et al., 2001, Hurwitz, 2009). Currently the 
revised McDonald criteria is the most commonly used method in diagnosis of MS. 
McDonald criteria focus on clinical, radiography, and laboratory of the lesions at different 
times and different areas (Karussis, 2014).    
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Table 1. The 2010 revised McDonald Criteria for Diagnosis of MS (Polman et al., 2011)  
 
 
Clinical Presentation Additional Data Needed for MS Diagnosis 
≥ 2 attacks; objective clinical 
evidence of ≥ 2 lesions or 
objective clinical evidence of 
1 lesion with reasonable 
historical evidence of a prior 
attack 
None 
≥ 2 attacks; objective 
clinical evidence of 1 lesion 
Dissemination in space, demonstrated by: ≥ 1 T2 lesion in at 
least 2 of 4 MS-typical regions of the CNS (periventricular, 
juxtacortical, infratentorial, or spinal cord); or Await a further 
clinical attack implicating a different CNS site. 
1 attack; objective clinical 
evidence of ≥ 2 lesions 
Dissemination in time, demonstrated by: Simultaneous 
presence of asymptomatic gadolinium-enhancing and 
nonenhancing lesions at any time; or A new T2 and/or 
gadolinium-enhancing lesion(s) on follow-up MRI, 
irrespective of its timing with reference to a baseline scan; or 
Await a second clinical attack. 
1 attack; objective clinical 
evidence of 1 lesion 
(clinically isolated 
syndrome) 
Dissemination in space and time, demonstrated by: For DIS: 
≥ 1 T2 lesion in at least 2 of 4 MS-typical regions of the CNS 
(periventricular, juxtacortical, infratentorial, or spinal cord); or 
Await a second clinical attack implicating a different CNS site; 
and For DIT: Simultaneous presence of asymptomatic 
gadolinium-enhancing and nonenhancing lesions at any time; 
or A new T2 and/or gadolinium-enhancing lesion(s) on follow-
up MRI, irrespective of its timing with reference to a baseline 
scan; or Await a second clinical attack. 
Insidious neurological 
progression suggestive of 
MS (PPMS) 
1 year of disease progression (retrospectively or 
prospectively determined) plus 2 of 3 of the following criteria:  
1. Evidence for DIS in the brain based on ≥ 1 T2 lesions in 
the MS-characteristic (periventricular, juxtacortical, or 
infratentorial) regions 
2. Evidence for DIS in the spinal cord based on ≥ 2 T2 lesions 
in the cord 
3. Positive CSF (isoelectric focusing evidence of oligoclonal 
bands and/or elevated IgG index) 
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1.1.4 Subtypes 
The vast variability of the clinical course of MS raised a need for a common language to 
describe the clinical courses and pathology of multiple sclerosis. This was addressed by 
the National MS Society in 1996, in defining four distinct clinical subtypes of MS:  
- Relapsing remitting MS (RRMS) is characterized by clearly defined disease 
relapses with full recovery. Periods between disease relapses are characterized 
by a lack of disease progression. 
 
- Secondary progressive MS (SPMS) is characterized by an initial relapsing-
remitting disease course followed by progression with or without occasional 
relapses, minor remissions and plateaus. 
 
- Primary progressive MS (PPMS) is defined as disease progression from onset 
with occasional plateaus and temporary minor improvements. The essential 
element in PPMS is a gradual, nearly continuously worsening with minor 
fluctuations, but no distinct relapses. 
 
- Progressive-relapsing MS (PRMS) is defined as progressive disease from onset, 
with clear acute relapses, with or without recovery, with periods between relapses 
characterized by continuing progression. 
 
Clinically isolated syndrome (CIS) was not included in the initial MS clinical description.  
CIS is now recognized as the first clinical presentation of a disease that shows 
characteristics of inflammatory demyelination that could be MS, but has yet to fulfil criteria 
of dissemination in time (Lublin et al., 2014).  
 
1.1.5 Pathology 
MS is considered primarily an inflammatory immune-mediated disease of the CNS in 
which auto-aggressive T-cells cross the blood–brain barrier (BBB) inflicting demyelination 
and axonal loss eventually leading to progressive disability (Ortiz et al., 2014). The MS 
inflammatory process is triggered by T-cells autoimmune reaction, targeting myelin 
antigens, possibly initiated through molecular mimicry mechanisms (cross-reactive 
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antigens expressed by viruses or other microorganisms, and myelin components) 
(Karussis, 2014). It is also proposed that due to malfunction in immunoregulatory 
mechanisms (such as those involving Th2, Th3, and CD8+ T-cells), myelin-specific T-
cells which maybe naturally present, expand to critical pathogenic numbers (Venken et 
al., 2010). T-cell activation leads to myelin and oligodendrocyte phagocytosis by 
macrophages.  Humoral immunity follows up by secretion of anti-myelin antibodies from 
B cells and subsequent fixation of complement and opsonization of the myelin sheath and 
the oligodendrocytes by macrophages (Bruck, 2005). Cytokines (IFN-𝛾 and TNF)  and 
chemokines released from these immune cells can be detected in MS lesions which can 
arise anywhere in the CNS (Cheng and Chen, 2014). However, the lesions are more likely 
to occur in optic nerve, spinal cord, brain stem, and periventricular areas. Furthermore, 
brain tissue immediately adjacent to the subarachnoid space, i.e. subpial gray matter, is 
especially vulnerable to demyelination (Stadelmann et al., 2011). The loss of myelin 
greatly enhances the propensity of axons for transport disturbance. Non-specific immune 
mediators, e.g. nitric oxide (NO), reactive oxygen species (ROS), and proteases lead to 
damage of naked and also myelinated axons as indicated by experimental studies. 
Neuronal antigens have been identified as targets of the immune reaction. Specific 
immune reactions against neurofilament, beta-synuclein, contactin-2/TAG-1, and 
neurofascin lead to CNS inflammation (Boretius et al., 2012). Such substances include 
free radicals, which can cause oxidative stress, and glutamic acid, which can cause 
excitotoxicity. Initial nonfatal damage to oligodendrocytes may initiate activation of an 
apoptotic cascade, perhaps by activation of death ligands or receptors such as Fas, FasL 
or Trail, that will result in delayed oligodendrocyte death. These apoptotic proteins can be 
activated by tumour necrosis factor, released from pro-inflammatory T cells in multiple 
sclerosis lesions, and have been demonstrated to promote oligodendrocyte cell death in 
vitro. Finally myelin sheath injury may render oligodendrocytes vulnerable to 
environmental toxins or viruses (Bruck, 2005). 
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Figure 4. Immune responses in multiple sclerosis. Hypothetical view of immune responses in 
acute multiple sclerosis lesions. Independent of the causative event, two steps are required to 
induce an immune response in the central nervous system (CNS): a pro-inflammatory milieu in the 
CNS, leading to up-regulation of major histocompatibility complex (MHC) molecules, costimulatory 
receptors and inflammatory cytokines and an antigen-driven acquired immune response. T- and B-
cell responses are primed in the peripheral lymphoid tissue by antigens that are released from the 
CNS or by cross-reactive foreign antigens. Dendritic cells that present neural antigens are strong 
stimulators of T-cell responses. After clonal expansion, T and B cells infiltrate the CNS. Clonally 
expanded B cells re-encounter their specific antigen, mature to plasma cells and release large 
amounts of immunoglobulin-γ (IgG) antibodies. These antibodies bind soluble or membrane-bound 
antigen on expressing cells. Clonally expanded CD8+ T cells also invade the brain and could 
encounter their specific peptide ligand, presented by glial or neuronal cells on MHC class I 
molecules. The recognition of specific MHC–peptide complexes on these cells prompts direct 
damage to expressing cells. CD4+ T cells migrate into the CNS and encounter antigens that are 
presented by microglial cells on MHC class II molecules. Reactivation of these cells leads to 
heightened production of inflammatory cytokines. These cytokines attract other immune cells, such 
as macrophages, which contribute to inflammation through the release of injurious immune 
mediators and direct phagocytic attack on the myelin sheath (Hemmer et al., 2002). 
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1.1.6 Treatment 
To date, no concrete remedy has been established for MS treatment although, various 
immunomodulatory agents reducing disease effects are available. Immunomodulatory 
therapies in MS are directed against the presumed autoimmune pathogenic mechanism 
of the disease (Hemmer et al., 2002). The first disease modifying treatment (DMT) 
approved by the Food and Drug Administration (FDA) was interferon beta-1b (IFNb-1b) 
in 1993 (Paty and Li, 1993). Since then structurally diverse MS drugs have been 
developed which are classified based on their specificity of their modulatory mechanism 
into: immunomodulators and immunosuppressants (Mulakayala et al., 2013).  
Immunomodulators like interferon beta (INFβ-1a, INFβ-1b) and glatiramer acetate (GA) 
moderate the malfunctioning of the lymphocytes by regulating their activation. They 
reduce the number of clinical relapses in the relapsing-remitting phase of the disease, 
and the formation of new lesions assessed by magnetic resonance imaging (MRI) 
(Pawate and Bagnato, 2015).  
Immunosuppressants reduce the number of circulating lymphocytes along with the 
healthy immune cells of the body, which may lead to considerable side effects. Each of 
these compounds has a unique mechanism of action and typically administered orally or 
intravenously. The most common orally administrated compounds include: cladribine, 
fumaric acid, teriflunomide, laquinimod. The example for intravenous compounds are 
cyclophosphamide (Kieseier et al., 2005, Mulakayala et al., 2013).  
With the development of monoclonal antibodies such as alemtuzumab, natalizumab, 
ocrelizumab, rituximab (all administered intravenously), daclizumab (subcutaneous 
admistration), and small molecules like fingolimod (taken orally), specific 
immunomodulation has become an important therapeutic option for MS treatment 
(Mulakayala et al., 2013).  
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1.2 Animal models of MS and EAE 
1.2.1 Overview  
MS is a complex human disease and a single animal model cannot address the spectrum 
of MS heterogeneity in clinical and radiological presentation (Pachner, 2011). Over the 
last decades different animal models have been used to study the pathogenic 
mechanisms of MS which could serve as a testing tool to study disease development and 
in order to establish novel therapeutic approaches (Procaccini et al., 2015). Animal 
models are precious resources in investigating CNS tissue which is the main target of 
multiple sclerosis. This could fill the gap of direct access to human tissues, biopsies, or 
autopsy samples which are rarely performed. The established animal models for MS are 
i) the experimental autoimmune/allergic encephalomyelitis (EAE); ii) Theiler's murine 
encephalomyelitis virus (TMEV) induced models and iii) toxin-induced models of 
demyelination, such as the cuprizone and the lyso-phosphatidylcholine (lyso- lecithin) 
(Table 2) (Procaccini et al., 2015, Gold, 2006). 
1.2.2 EAE 
EAE is the oldest and most frequently used experimental model to study immune 
regulation of MS (Webb, 2014). This model is studied in many different species, including 
primates and rodents and is a CD4+ Th1 cell mediated autoimmune disease in CNS 
(Linker and Lee, 2009, Skundric, 2005). EAE model is heterogeneous and influenced by 
the selected antigen, species and the genetic background (Pachner, 2011). The specific 
mechanisms that lead to the onset of the disease, spontaneous recovery and relapse are 
not completely understood. It seems that upon EAE immunization pro-inflammatory 
cytokines released within the CNS by infiltrating immune cells, or locally produced in 
response to CNS inflammation, may contribute to increase vascular permeability, 
inflammatory cell extravasation, antigen presentation, glial activation and the destruction 
of oligodendrocytes and myelin (Giatti et al., 2013). No single EAE model can fully 
reproduce the spectrum of MS and instead different genetic backgrounds need to be 
immunized with different antigens in order to provide the immunological and 
histopathological aspects of the MS (Kuerten et al., 2008). 
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1.2.3 EAE subtypes 
EAE is induced through two major subtypes: 1) active immunization with myelin peptides 
2) passively or adoptively transferred EAE (Fig. 5) (Skundric, 2005). In active EAE, 
susceptible strains of mice are immunized with an appropriate myelin antigen or peptide 
emulsified in a mineral oil-based adjuvant (Freund's adjuvant) with an additional heat-
inactivated mycobacteria (complete Freund's adjuvant, CFA) (Linker and Lee, 2009). 
Some models (especially in mice) also require the intraperitoneal injection of pertussis 
toxin on the day of immunization and 48 hrs later which play a role in the breakdown of 
the blood-brain-barrier and also deplete regulatory T cells, thus enhance autoimmune 
reactions (Racke, 2001). In all cases, the relevant immunogen is derived from self-CNS 
proteins such as myelin basic protein (MBP), proteolipid protein (PLP) or myelin 
oligodendrocyte glycoprotein (MOG) (Linker and Lee, 2009, Gold, 2006).  
 
EAE could also be induced through the passive or adoptive transfer by injecting mice with 
activated, myelin-specific T cells (Racke, 2001). Classic models of adoptive transfer 
involve the immunization of donor mice with PLP-derived peptides, isolation of peripheral 
lymphoid cells after 7/10 days of culture, in vitro re-stimulation with myelin peptide and 
subsequent transfer into naïve recipients. These models were useful to demonstrate the 
central role of CD4+ T cells in the pathogenesis of EAE. The limitations of this method is 
that the T cells directed against a specific antigenic epitope and the encephalitogenic 
capacity of transferred T cells not necessarily reflects the in vivo condition in donor 
animals. The decreased capability of knockout T cells to transfer the disease could, for 
example, reflect defective antigen presentation in the donor animals, rather than alteration 
in T cell functions from lesions. This aspect, combined with the pleiotropic nature of 
immune gene expression, makes it difficult to use the adoptive transfer model to define 
the contributions of individual genes to encephalitogenic T cell function (Procaccini et al., 
2015). 
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    Table 2. Characteristics of different mouse models of MS (Procaccini et al., 2015) 
Figure 5. A) Methods of EAE induction. Active induction involves injecting animals with myelin 
proteins such as MOG, PLP, or MBP along with Mycobacterium tuberculosis and pertussis toxin, 
both of which act as immunostimulants. In adoptive transfer, the lymph nodes of immunized 
animal (with myelin antigens) are removed and antigen-primed lymphocytes are extracted and 
cultured in vitro. These activated immune cells are then injected into another animal to induce the 
disease (MS Discovery Forum). B) 5-points scale of EAE clinical score in mice (Hooks Laboratory, 
EAE protocol). 
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1.2.4 MOG induced EAE  
In the C57BL/6 mouse strain, the H-2b MHC haplotype governs the ability to induce 
encephalitogenicity and to develop demyelinating autoantibodies in response to mouse 
or rat MOG. Transfer of these demyelinating anti-MOG antibodies also enhances 
demyelination and exacerbates disease severity in mouse models of EAE. Over the last 
15 years, the avenue of genetically engineered mice has greatly promoted the 
investigation of EAE pathomechanisms, particularly after backcrossing strains on the 
C57BL/6 background. MOG-EAE in the C57BL/6 mouse is one of the most widely used 
models in neuroimmunological research (Linker and Lee, 2009).  
EAE inducing antigen has specific activation pattern and produce particular symptoms 
and intensity. In SJL mice PLP139-151 EAE induction leads to relapsing-remitting disease 
while MOG1-20 or MOG92-106 develop either acute or chronic sustained EAE (Skundric, 
2005). In mice MOG35-55 peptide can induce EAE in C57BL/6 mice or Biozzi ABH mice 
resulting in a relapsing-remitting or chronic disease course (Linker and Lee, 2009). While 
several peptides could induce T cell responses, only MOG35-55 is able to induce CNS 
autoimmunity upon immunization (Rangachari and Kuchroo, 2013). MOG35-55-induced 
EAE is generally characterized by CD4+ T cells, macrophages and granulocytes 
detection within the lesions throughout the disease (Kuerten et al., 2008). MOG35-55-
driven EAE analysis also provide information on CD8+ T cell function in CNS 
autoimmunity. CD8+ T cells have a role in MS pathology since it is shown that CD8+ T 
cells outnumber CD4+ T cells in MS lesions by as much as 10 to 1 (Rangachari and 
Kuchroo, 2013). 
The clinical course of EAE, depending on the strain and the antigen used, will manifest in 
the form of weakness in 10 to 15 days after immunization (Racke, 2001). The weakness 
in EAE is usually associated with flaccidity, that is, decreased muscle tone. Most EAE 
investigators use a relatively subjective visual assessment grading scale of zero to five 
for grading weakness rather than objective neurobehavioral analyses (Pachner, 2011). 
This scaling is characterized by an ascending paralysis beginning at the tail, followed by 
hindlimb and forelimb paralysis (Fig 5B) (Procaccini et al., 2015). 
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1.3 Glial cells and MS  
1.3.1 Glia 
The nervous system is formed by two major cell types, neurons and glial cells (Araque 
and Navarrete, 2010). Glial cells also referred as neuroglia or glia, are non-neuronal cells 
in the CNS. They represent the most abundant cell population in the central nervous 
system and for years they have been thought to provide just structural and trophic support 
to neurons (Jessen and Mirsky, 1980). Glial cells are essential for the organization and 
function of the nervous system. In addition to their “traditional” roles in providing 
nourishment and support for neurons, glial cells regulate synaptic transmission, maintain 
the blood-brain barrier, mediate communication between the nervous and immune 
systems and monitor the nutritional state of organisms. Highlighting their critical role 
during embryogenesis and in postnatal life, several developmental, degenerative, and 
inflammatory disorders of the nervous system have been associated with deficits in glial 
cell function (Boesmans et al., 2015). 
There are three types of glial cells in the mature central nervous system: astrocytes, 
oligodendrocytes, and microglia (Figure 6) (Nagelhus et al., 2013). Astrocytes, the most 
numerous cell type in brain, fill most of the space between neurons and blood vessels. 
Recent studies show that astrocytes have strong impact on neuronal function, neuronal 
development, and brain ageing. Astrocytes regulate extracellular ion concentration, water 
homeostasis and the acid-base balance in the brain. They also actively modulate synaptic 
transmission by releasing neuroactive compounds (Araque and Navarrete, 2010, 
Nagelhus et al., 2013). Oligodendrocytes, which are also restricted to the central nervous 
system, lay down a laminated, lipid-rich wrapping called myelin around axons. Myelin has 
important effects on the speed of the transmission of electrical signals. In the peripheral 
nervous system, the cells that elaborate myelin are called Schwann cells (Neuroscience 
/ edited by Dale Purves: Third Edition). Microglia are hematopoietic in origin, have 
phagocytic capability, and are found in the CNS. They perform functions related to the 
immune response in a wide variety of neuroinflammatory processes. Their high functional 
plasticity is demonstrated by the fact that they are activated by a number of different 
diseases that affect the CNS. Activated microglia express different types of cell surface 
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molecules, including Fc receptors, scavenger receptors, cytokine and chemokine 
receptors, CD11b, CD11c, CD14, and major histocompatibility complex (MHC) molecules 
(Lopategui Cabezas et al., 2014). 
  
  
 
 
Figure 6. Varieties of neuroglial cells. (A) Tracings of an astrocyte, (B) an oligodendrocyte, 
(C) a microglial cell. (D) Astrocytes in tissue culture, labelled (red) with an antibody against 
an astrocyte-specific protein. (E) Oligodendroglial cells in tissue culture labelled with an 
antibody against an oligodendroglial-specific protein. (F) Peripheral axon are ensheathed 
by myelin (labelled red) except at a distinct region called the node of Ranvier. The green 
label indicates ion channels concentrated in the node; the blue label indicates a molecularly 
distinct region called the paranode. (G) Microglial cells from the spinal cord, labelled with a 
cell type-specific antibody. Inset: Higher-magnification image of a single microglial cell 
labelled with a macrophage-selective marker (Neuroscience / edited by Dale Purves: Third 
Edition). 
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 1.3.2 Glial related neurological disorders 
Glial cells are associated to numerous neurological disorders such as Creutzfeldt-Jakob 
disease, HIV-associated dementia, cerebral infarct, ALS, and epilepsy (Steinhauser and 
Seifert, 2012, Lopategui Cabezas et al., 2014). Inflammatory response of glial cells could 
exacerbate pathogenesis of neurodegenerative and autoimmune diseases such as 
Alzheimer’s disease, Parkinson’s disease and Multiple sclerosis. In these diseases, 
inflammation occurs in order to clean up the lesion and to limit disease progression. 
However, prolonged and sustained inflammatory reactions could cause cytotoxic effects 
and increase the severity of the disease. Immunoreactive glial cells release 
proinflammatory cytokines, chemokines and deleterious free radicals in 
neurodegenerative diseases (Kempuraj et al., 2013).  
 
1.3.3 Oligodendroglia and myelin 
A series of highly complex coordinated processes regulate the development of healthy 
and functional nervous system during fetal life (From et al., 2014). Myelinogenesis, the 
establishment of the myelin sheath, is critical for optimization of conduction velocity, as 
well as maturation, survival, and regenerative capacity of the axons (Paz Soldan and 
Pirko, 2012). Myelin is a lipoprotein ensheathment of the axons with about 1 μm thickness 
(Patel and Balabanov, 2012). The composition of myelin is ~70% lipid and 30% protein, 
which is in contrast to other membranes typically made of 30–50% lipid. Various classes 
of lipids are present in oligodendrocytes and myelin membranes, including cholesterol, 
phospholipids, and glycosphingolipids (Jackman et al., 2009). Major myelin proteins 
include ~50% proteolipid protein (PLP), a group of myelin basic protein (MBP) isoforms 
(~30% of the total), and minor proteins such as MOG, CNPase, MAG (Mallucci et al., 
2015). Myelinated axons conduct action potentials by a saltatory mode between nodes of 
Ranvier to increase both the speed and energy efficiency of nerve conduction (Mitew et 
al., 2014). In rodents and humans, myelinogenesis occurs predominantly postnatally 
(within the first 3 weeks and 2 years, respectively), by regulated steps that ensure 
myelination at the appropriate time and location (From et al., 2014).  
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Oligodendrocytes are the myelin producing cells in the CNS (Bankston et al., 2013). The 
generation of myelin during development involves a finely-tuned pathway of 
oligodendrocyte precursor cell (OPC) specification, proliferation and migration followed 
by differentiation and the subsequent myelination of appropriate axons (Mitew et al., 
2014). OPCs originate in sequential waves from particular germinal regions in specific 
areas of the developing CNS (Mitew et al., 2014). Once generated, they migrate towards 
their destinations where they differentiate into mature oligodendrocytes (Bradl and 
Lassmann, 2010). Two different populations of oligodendrocyte precursor cells have been 
identified during development (i) one type of OPC is characterized by the expression of 
plp/dm-20 and these do not depend on PDGF-AA growth factor; (ii) the second and 
largest population of oligodendrocyte precursor cells does depend on this growth factor 
and express PDGFRα (Clemente et al., 2013). The oligodendrocytes differentiation 
involves signalling processes between the Notch1 receptor, its ligand Jagged 1 located 
on the axonal surface, and c-secretase (Bradl and Lassmann, 2010). Only maturing 
oligodendrocytes initiate and maintain myelin formation within a brief period of time during 
differentiation. Therefore, a tremendous amount of proteins and other biomolecules 
should be synthesized, sorted, and trafficked in short period of time (Bryant et al., 2009). 
For instance, MBP is targeted by transport of its mRNA which is assembled into granules 
in the soma of oligodendrocytes, transported along processes, and then localized to the 
myelin membrane (Bradl and Lassmann, 2010). In adult CNS, 5% of all cells are OPCs 
that retain the capacity to proliferate, migrate, and differentiate into oligodendrocytes. 
These endogenous oligodendrocyte precursor cells react to damage in demyelinating 
diseases, like MS, representing a key element in spontaneous remyelination (Crawford 
et al., 2014). 
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1.3.4 Oligodendroglia in MS and EAE   
Oligodendroglial diseases invariably produce some degree of demyelination, which is 
thought to underlie their clinical signs and symptoms. The most directly associated 
disorder with oligodendroglial injury is multiple sclerosis (Morrison et al., 2013). MS 
oligodendrocyte injuries could be studied under 2 categories of specific and non-specific 
injuries (Patel and Balabanov, 2012).  
Specific mechanisms of oligodendrocyte injury are modulated by T and B cells. CD8+ 
lymphocytes, the MHC class I restricted T cells, are involved in antigen-specific 
cytotoxicity and are the most common lymphocyte subset identified in acute MS lesions. 
CD8+ cytotoxicity is mediated through cell surface FasL, IFN-γ, TNF-α, lymphotoxin, 
granzyme B, and perforin. In inflammation, oligodendrocytes upregulate the expression 
of MHC class I molecule, as well as Fas, IFN-γ and TNF-α receptors rendering them direct 
targets of CD8+ cells (Patel and Balabanov, 2012, Mars et al., 2011). Activated helper T 
cells (TH) 1 produce proinflammatory, cytotoxic factors of TNF-α, IFN-γ, which promote 
oligodendrocyte death and demyelination (Cudrici et al., 2006). The γδ T cells (not MHC 
restricted lymphocytes) are also present in the acute lesions and destroy 
oligodendrocytes by expressing stress proteins such as heat-shock proteins and alpha-
crystallin (Harirchian et al., 2012). B-cells can exert effector functions as antigen-
presenting cells, by cytokine and antibody production. Memory B-cells serve as highly 
efficient antigen-specific APCs and myelin-reactive memory B-cells can be found in the 
peripheral blood of MS patients (von Budingen et al., 2015).   
Non-specific injury occurs as a complication of the inflammatory process. Monocytes, 
microglia, and astrocytes present in the lesions express receptors (MHC class II, Toll-like, 
and Fc receptors) and secrete a variety of molecular signals required for propagation of 
the inflammatory process. They also produce factors with cytotoxic activity, which 
contribute to the expansion of tissue injury, including proteolytic and lipolytic enzymes, 
reactive oxygen and nitrogen species (O2 −, H2O2, OH−, NO, ONOO−), and excitotoxins 
(Patel and Balabanov, 2012). The most vulnerable cells of the CNS to such factors are 
oligodendrocytes and this is due to ceramide, a component of the myelin sphingolipids 
which can activate pro-apoptotic signalling in response to oxidative injury (Schenck et al., 
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2007). The other facts making oligodendrocytes prone to oxidative stress are their high 
metabolic rate (necessary for myelin maintenance) and large amounts of protein output 
(making it susceptible to endoplasmic reticulum stress) (Patel and Balabanov, 2012). 
In MS, successful remyelination in the injured CNS is dependent on the survival and 
differentiation of oligodendrocyte progenitor cells rather than regeneration by mature, 
myelinating oligodendrocytes (Moore et al., 2015). Nevertheless, remyelination efficiency 
is generally low and repair gradually fails as the disease progresses over time, ultimately 
leading to significant clinical disability. This failure of remyelination was shown to be 
mainly due to a blockade of oligodendroglial differentiation and maturation (Gottle et al., 
2015). In situ analysis of active MS lesions suggested that OPCs are more vulnerable to 
injury than mature oligodendrocytes within the same lesion site. In vitro and animal 
studies also indicated enhanced vulnerability of OPCs to proinflammatory mediators, 
including TNF-a, compared with more mature oligodendrocyte lineage cells (Moore et al., 
2015).  
Although, EAE recapitulates many critical events of MS pathogenesis including 
oligodendrocyte cell injury and death, traditional EAE has certain limitations. It cannot 
delineate oligodendrocyte response to injury or isolate its most intricate mechanisms 
(Patel and Balabanov, 2012). To date, various animal models are developed to study 
different aspects of oligodendrocytes remyelination including: lysolecithin and ethidium 
bromide focal injections, oral cuprizone administration, and inflammatory models. The 
inflammatory process is critical in inducing OPC activation and subsequent remyelination 
as several models of inflammation-induced demyelination show spontaneous 
remyelination. However, in MOG induced EAE remyelination is not very extensive, 
perhaps due to the dense infiltration of macrophages and microglia in the lesion over 
prolonged periods of time. The only indication of impressive levels of remyelination in 
EAE is observed in focal models of cortical demyelination involving immunization with 
subclinical doses of MOG and injection of pro-inflammatory mediators (Miron et al., 2011).  
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1.4 FGF/FGFR and MS 
1.4.1 Fibroblast Growth Factors (FGF)  
The fibroblast growth factor (FGF) family is a group of multifunctional signalling molecules 
which are involved in numerous cellular processes such as proliferation, migration, and 
differentiation and various physiological processes such as mitogenesis, angiogenesis, 
embryogenesis, regulating metabolism and wound healing (Teven et al., 2014). FGF 
growth factors have been identified in various multicellular organisms from the nematode 
to humans (Itoh, 2007). In mammals, the FGF family consist of 22 structurally related 
proteins (Woodbury and Ikezu, 2013). Based on the modes of action, mechanisms of 
secretion and ultimate biological consequences, these proteins have been further 
grouped into several subfamilies, each sharing both genetic and functional similarity. 
They include FGF1 subfamily (FGF1 and FGF2), FGF4 subfamily (FGF4, FGF5, FGF6), 
FGF7 subfamily (FGF3, FGF7, FGF10 and FGF22), FGF8 subfamily (FGF8, FGF17 and 
FGF18), FGF9 subfamily (FGF9, FGF16 and FGF20), FGF19 subfamily (FGF19, FGF21 
and FGF23), and FGF homologous factor (FHF) subfamily (FGF11 (FHF3), FGF12 
(FHF1), FGF13 (FHF2), and FGF14 (FHF4)) (Imamura, 2014). FGFs share a similar 
internal core and have a characteristically high binding affinity for both heparin and 
fibroblast growth factor receptors (FGFRs) (Teven et al., 2014). They exert their activities 
mainly via paracrine and/or autocrine modes of action by activating one or more cell 
surface receptor tyrosine kinases (Imamura, 2014).  
FGF-binding protein (FGFBP) is a carrier protein that activates FGFs by releasing them 
from the extracellular matrix, where they are bound by heparan sulphate 
glycosaminoglycan (HSGAG). FGFBP has been shown to increase FGF2-dependent 
proliferation of fibroblast cells and may have an important role in the development of some 
cancers. Other activators of FGF signalling include fibronectin leucine-rich 
transmembrane protein 3 (FLRT3), which facilitates FGF8 activity through the MAPK 
pathway (Beenken and Mohammadi, 2009). FGFs are crucial to development of the CNS, 
which explains their importance in adult neurogenesis. During development, high levels 
of FGF2 are detected from neurulation onwards. Moreover, developmental expression of  
   Introduction 
   
21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Structural features of FGF ligands and their specific receptors. A. 
FGF1, showing its 12 antiparallel β-sheets and amino and carboxyl termini (Beenken 
and Mohammadi, 2009). B. the 22 FGFs, grouped according to their subfamily. The 
family of FGF receptors contains four main members (FGFR1 to 4) and each receptor 
could be activated with more than a single ligand (Guillemot and Zimmer, 2011). 
. 
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FGF2 and its receptors is temporally and spatially regulated, concurring with development 
of specific brain regions including the hippocampus and substantia nigra pars compacta 
(Woodbury and Ikezu, 2013). FGF2 regulates neural stem cells propagation both in vitro 
and in vivo (Gritti et al., 1996).  
The involvement of FGF signalling in human disease is well documented. Deregulated 
FGF signalling can contribute to pathological conditions either through gain or loss of 
function. For instance, mutations in FGF23 (gain of function) in autosomal dominant 
hypophosphataemic rickets, in FGF10 (loss of function) in lacrimo-auriculo-dento-digital 
syndrome (LADD syndrome), FGF3 (loss of function) in deafness and FGF8 (loss of 
function) in Kallmann syndrome (Beenken and Mohammadi, 2009). FGFs are also 
involved in the inflammatory process. FGF-1 and FGF-2 upregulated in inflammatory 
disorders such as bowel syndrome, Crohn’s disease, ulcerative colitis, and rheumatoid 
arthritis. Other reports have suggested that FGF-1 and FGF-2 are secreted by and may 
act as immunoregulators of infiltrating neutrophils, monocytes, macrophages, and T 
lymphocytes, often in tandem with powerful inflammatory cytokines (Haddad et al., 2011). 
FGF2 has been identified as a neuroprotective factor in preventing disease and in milder 
course of EAE (Woodbury and Ikezu, 2013). More severe EAE disease course was 
observed in FGF2(−/−) mice vs. FGF2(+/+) mice, specifically measured by increased 
infiltration of macrophages/microglia and CD8+ T-cells, increased nerve fibre 
degeneration, and decreased remyelination of axons, suggesting a protective role of 
FGF2 (Rottlaender et al., 2011). 
 
1.4.2 FGF Receptors (FGFR) 
The effects of FGF ligands are mediated by binding to four FGF receptors (FGFR1–4) 
and their splice variants (Jiang et al., 2015). FGFRs are tyrosine kinase receptors (RTK) 
that contain a heparin-binding sequence, three extracellular immunoglobulin (Ig)-like 
domains (D1eD3), an acidic box, a hydrophobic transmembrane domain, and a split 
intracellular tyrosine kinase domain (Teven et al., 2014). The IgIII domains of FGFR1–3 
are encoded for by exons 7–9. Inclusion of exons 8 and 9 is mutually exclusive, producing 
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the IIIb and IIIc splice isoforms (Morita et al., 2014). This alternative RNA splicing of 
FGFRs 1–3 is an essential determinant of ligand binding specificity. The IIIb and IIIc splice 
forms are regulated in a tissue specific manner, such that the b isoform is restricted to 
epithelial lineages and the c isoform is preferentially expressed in mesenchymal lineages 
(Zhang et al., 2006). The diversity in FGF signalling is due, in part, to different FGF/FGFR 
combinations. Additionally, alternative splicing in the FGFR Ig-like domains generates 
additional receptor isoforms with novel ligand affinities (Haddad et al., 2011). Finally, 
effector cells will usually express different heparan-sulfates at their surface, which are 
responsible for stabilizing FGF/FGFR complexes and enhancing FGFR downstream 
signalling (Haddad et al., 2011).  
FGF1 is known to activate all seven FGFR subtypes, while FGF2 shows greater receptor 
specificity, activating only FGFR1c, FGFR2c, FGFR3c, FGFR4 and, to a lesser degree, 
FGFR1b (Imamura, 2014). The FGFR activation is in a HSGAG-dependent manner. Upon 
binding of ligand and HSGAG, FGFRs dimerize, enabling the cytoplasmic kinase domains 
to transphosphorylate on “A” loop tyrosines to become activated. A loop phosphorylation 
is followed by phosphorylation of tyrosines in the C tail, kinase insert and juxtamembrane 
regions. The two main intracellular substrates of FGFR are phospholipase C (PLC) γ1 
(also known as FRS1) and FGFR substrate 2 (FRS2). Phosphorylation of an FGFR-
invariant tyrosine (Y766 in FGFR1) at the C tail of FGFR creates a binding site for the 
SH2 domain of PLCγ and is required for PLCγ phosphorylation and activation. 
Phosphorylation of FRS2 is essential for activation of the Ras–mitogen-activated protein 
kinase (MAPK) and phosphoinositide 3-kinase–AKT signalling pathways (Figure 8) 
(Beenken and Mohammadi, 2009). 
FGF/FGFR interactions comprise a large signalling network, playing key roles in different 
physiological processes and functions including embryonic development and normal 
tissue homeostasis via ligand binding of the extracellular domains in FGFRs (Tchaicha et 
al., 2014). Germline gain-of-function mutations in FGFR contribute in many skeletal 
syndromes, Kallmann syndrome. Most of the FGFR mutations are ligand independent, 
but a few manifest only during ligand binding. Apert’s syndrome is the result of such 
mutation which enhances ligand binding of inappropriate ligands (Beenken and 
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Mohammadi, 2009). Most of the FGFR3 mutations found in cancer are identical to the 
FGFR2 mutations involved in skeletal disorders. Kinase domain loss-of-function 
mutations also occur in FGFR2 and FGFR3 in LADD syndrome and in FGFR2 in 
melanoma (Rohmann et al., 2006). Direct inhibition of FGFRs may prove to be of clinical 
value. Inhibitory molecules such as NDGA that target a specific subcellular compartment 
may be beneficial in the inhibition of activated receptors such as FGFR3 that signal from 
the same compartment (Meyer et al., 2008). 
Figure 8. Fibroblast growth factor receptor (FGFR) signalling. Structurally unresolved 
regions are shown as grey lines. Amino-terminal and carboxy-terminal lobes of the kinase 
domain are coloured green and red, respectively. The two major intracellular targets, 
phospholipase (PLC)γ1 and FGFR substrate 2α (FRS2α), are shown. A loop, activation loop; 
GRB2, growth factor receptor bound 2; HS, heparan sulphate; IP3, inositol-1,4,5-trisphosphate; 
MAPK, mitogen-activated protein kinase; MAPKK, mitogen-activated protein kinase kinase; 
PH, pleckstrin homology domain; PIP2, phosphatidyl inositol-4,5- bisphosphate; PKC, protein 
kinase C; PTB, phosphotyrosine binding domain; PTK, protein tyrosine kinase; SH, Src 
homology domain (Beenken and Mohammadi, 2009). 
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1.4.3 FGFR2 
Fgfr2 gene at human chromosome 10q26 encodes FGFR2b and FGFR2c isoforms due 
to alternative splicing (Katoh and Katoh, 2009). FGFR2b isoform is expressed in epithelial 
cells, and that the FGFR2c is expressed in mesenchymal cells (Orr-Urtreger et al., 1993). 
FGFR2b on epithelial cells is a high affinity receptor for FGF1, FGF3, FGF7, FGF10 and 
FGF22 while the FGFR 2c isoform on mesenchymal cells is a high affinity receptor for 
FGF1, FGF2, FGF4, FGF6, FGF9, FGF16 and FGF20. FGFR 2b and FGFR2c show 
distinct expression domain and ligand specificity (Zhang et al., 2006, Morita et al., 2014).  
The lineage-specific expression of the IIIb and IIIc isoforms of FGFRs enables interaction 
between the epithelial and mesenchymal layers during development in response to 
different FGFs (Eswarakumar et al., 2005). FGF7, FGF10, and FGF22 constitute a 
subfamily among the FGF family. FGF7, induced by PDGF, IL-1, IL-1ß or TNF-α, is 
secreted from fibroblast, smooth muscle cells, endothelial cells, skin dermis, and  γδT 
cells to promote tissue repair (auf demKeller et al., 2004). FGF10 is secreted from 
mesenchymal cells to orchestrate morphogenesis of gastrointestinal tract, respiratory 
tract, limb, and other organs or tissues. FGF22 is secreted from cerebellar granule cells 
to regulate synapse formation. FGF7, FGF10 and FGF22 transduce signals through 
FGFR2b on epithelial cells to regulate embryogenesis and adult tissue homeostasis 
(Katoh and Katoh, 2009).   
It has been shown that Fgfr2-/- mice die at E10.5 due to defects in the placenta. However, 
selective disruption of the FGFR2b isoform leads to severe impairment in the 
development of the lung, limbs and other tissues resulting in lethality immediately after 
birth. Disruption of the FGFR2c isoform, on the other hand, results in impairment in skull 
and bone development, but the mutant mice are viable (Eswarakumar et al., 2005). 
FGFR2b and FGFR2c function as FGF receptors transducing FGF signals to RAS-ERK 
and PI3K-AKT signalling cascades through FRS2, and also to DAG-PKC and IP3-
Calmodulin signalling cascades through PLCγ. FGFR2b and FGFR2c with extracellular 
Ig-like domains and cytoplasmic tyrosine kinase domain are almost identical except the 
latter half of the third immunoglobulin-like domain (Katoh and Katoh, 2009).  
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1.4.4 FGFR2 related disorders  
Fgfr2 mutations around the third Ig-like domain result in FGFR2 signalling activation due 
to the creation of autocrine FGF signalling loop. While mutations within tyrosine kinase 
domain results in FGFR2 signalling activation due to the release of FGFR2 from 
autoinhibition (Katoh and Katoh, 2009). Most of the Fgfr mutations are ligand 
independent, but a few such as Ser252Trp and Pro253Arg in the ectodomain of Fgfr2 
manifest only during ligand binding. These mutations cause Apert syndrome by 
enhancing ligand binding affinity and promoting the binding of inappropriate ligands 
(Beenken and Mohammadi, 2009). Fgfr2 mutations that enhance receptor activity cause 
abnormal fusions of the bones within the skull and limbs in Apert, Crouzon, Jackson-
Weiss and Pfeiffer syndromes (Eswarakumar et al., 2005). In contrast, Fgfr2 mutations 
that reduce receptor activity cause bone hypoplasia within the skull and limb in Lacrimo-
auriculo-dento-digital (LADD) syndrome (Eswarakumar et al., 2005).  
Severe defects in epithelial organogenesis occur in mice lacking Fgf10 or its receptor, 
FGFR2b, causing underdevelopment of many organs, such as salivary glands and lungs 
(Lombaert et al., 2013). Genetic studies in mouse show that Fgfr2 mutations disrupt 
skeletal development by altering the ability of the receptor to regulate osteoprogenitor cell 
proliferation and differentiation: increased FGFR2 function enhances proliferation and 
differentiation (Neben et al., 2014). FGFR2 and its ligands have been proved to play an 
important role in breast cancer development and progression. Genome-wide analysis has 
identified four SNPs (single nucleotide polymorphism) in the intron 2 of Fgfr2 gene, which 
were associated with a higher incidence of breast cancer. Moreover, the activation of 
FGFR2 triggered aggressive growth of breast cancer cells in vivo. FGFR2 is suggested 
to be essential for induction of self-renewal and cell maintenance of human breast tumour 
initiating cells (Czaplinska et al., 2014).   
Protein kinases with conserved amino-acid sequence share the catalytic domain with 
similar three-dimensional structure. Small-molecule compounds fitting into the ATP-
binding pockets of protein kinases have been developed for cancer therapeutics (Garber, 
2006). PD173074, SU5402, AZD2171, and Ki23057 are representative small-molecule 
FGFR inhibitors (Katoh and Katoh, 2009). Several kinds of molecular-targeted therapies 
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to the FGFR2 signalling pathway have been reported in various cancers. Ki23057, which 
inhibits autophosphorylation of FGFR2 IIIb decreased the growth of biliary tract cancer 
cells. In endometrial cancer cells harbouring activated mutations of Fgfr2, knockdown of 
Fgfr2 using short hairpin (sh) RNA or treatment with a pan-FGFR inhibitor (PD173074) 
caused cell cycle arrest and cell death (Matsuda et al., 2012). Other therapeutics targeted 
to FGFR2 include human antibody, peptide mimetic, RNA aptamer, small interfering RNA 
(siRNA), and synthetic microRNA (miRNA) (Katoh and Katoh, 2009). 
 
1.4.5 FGFR2 in oligodendrocyte and MS  
FGF/FGFR interactions play diverse roles in proliferation, migration, differentiation, and 
survival of both neurons and glial cells including oligodendrocytes, the myelin-forming 
cells of the CNS (Furusho et al., 2011). A key feature of this regulation is the differential 
expression of three FGF receptors during oligodendrocyte development. FGFR1 is 
expressed at all stages of the oligodendrocyte lineage, FGFR2 appears only in 
differentiated oligodendrocytes, FGFR3 expression increases from the early to late 
progenitor stage and then is downregulated as oligodendrocytes begin terminal 
differentiation, and FGFR4 is not expressed by oligodendrocyte lineage cells (Furusho et 
al., 2015). Only in a short window of time during maturation the oligodendrocytes initiate 
myelin formation (Bryant et al., 2009). Stimulation of oligodendrocyte process outgrowth 
and myelin-like membrane formation occurs with selective activation of FGFR2 in vitro 
(Fortin et al., 2005). In vivo FGFR2 is expressed by oligodendrocytes in myelinated fiber 
tracts of adult rodent brain, spinal cord, and optic nerve and is present in purified myelin. 
The expression of FGFR2 by neurons and astrocytes is low or absent (Kaga et al., 2006).  
 
The most abundant tyrosine-phosphorylated protein in oligodendrocytes is the 120-kd 
isoform of FGFR2 and it is phosphorylated even in the absence of FGF2, suggesting a 
potential ligand independent function for this receptor. Furthermore, FGFR2, but not 
FGFR1, is associated with lipid raft microdomains in oligodendrocytes and myelin (Bryant 
et al., 2009). Conditional knockout mice that lack Fgfr2 and the myelin protein CNP 
display dopamine-related hyperactive behavior (Kaga et al., 2006). Interestingly, down-
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regulation of both CNP and Fgfr2 mRNA expression occurs in schizophrenia, a condition 
that also is intimately related to the brain dopamine system (Bryant et al., 2009).  
 
Remyelination, which may restore nerve conduction and protect axons, is significantly 
greater in early stage of MS lesions than in chronic disease. Failed differentiation of 
oligodendrocyte lineage cells may contribute to poor remyelination in chronic MS lesions 
and prolonged neurological deficits. Multiple molecular signaling pathways inhibit 
differentiation of oligodendrocyte progenitor cells and limit remyelination in experimental 
models. Modifying inhibitory signals in lesion areas could potentially enhance functional 
recovery in MS patients by improving the remyelination capacity of immature 
oligodendrocytes that persist in MS lesions (Mierzwa et al., 2013).  
 
Selective activation of FGFR2 leads to stimulation of oligodendrocyte process outgrowth 
and myelin-like membrane formation in cultures, whereas inhibition of FGFR2 function by 
blocking antibodies leads to attenuation of these responses (Fortin et al., 2005). During 
remyelination, FGF2 may play a role in directly regulating oligodendrocyte lineage cell 
responses and may also act through paracrine or autocrine effects on astrocytes, which 
are known to synthesize other growth factors and immunoregulatory molecules that 
influence oligodendrocyte lineage cells (Messersmith et al., 2000). FGF signaling plays a 
key role during the regeneration of oligodendrocytes and myelin. FGF2 and/or FGFR is 
upregulated in MS patients and in mouse models of demyelination (Clemente et al., 
2011).  
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2 OBJECTIVES 
  
The FGF/FGFR interactions regulate a broad spectrum of physiological and pathological 
processes. Various research studies attribute a critical role to FGFR2 in oligodendroglial 
organization and function. Therefore, we hypothesized that deletion of Fgfr2 in 
oligodendrocytes would lead to a more severe course of EAE, leading to higher 
inflammation and neurodegeneration. The aim of this study was to characterize the role 
of FGFR2 in experimental autoimmune encephalomyelitis, the most common animal of 
multiple sclerosis.   
 
Study Objectives 
1. To determine the proliferative and differentiate changes of oligodendrocytes in 
Fgfr2ind-/- mice. 
2. To study the expression and regulation patterns of oligodendroglial Fgfr2 knockout 
downstream signaling pathway in Fgfr2ind-/- mice in different CNS regions. 
3. To investigate the potential role of oligodendroglial FGFR2 in disease severity in 
acute and chronic experimental autoimmune encephalomyelitis. 
4. To characterize the morphology and immunohistochemistry of MOG35-55-EAE 
lesions in Fgfr2ind-/- mice. 
5. To evaluate the oligodendroglial FGFR2 downstream signaling pathway in EAE.  
6. To investigate the pharmacological effects of GA in MOG35-55-EAE induced 
Fgfr2ind-/- mice. 
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3 MATERIALS AND METHODS 
  
3.1 Materials 
3.1.1 Mice 
Mice line Supplier Animal facility 
Fgfr2fl/fl 
Michael Sendtner, Würzburg 
(Blak et al., 2007) 
JLU, Central Animal facility, 
Frankfurter strasse 110, Giessen, 
Germany. PLP Cre
ERT 
The Jackson Laboratories, 
Bar Harbor, ME, USA 
C57BL/6J 
 
 
3.1.2 Genetic background 
Mouse strain Treatment Abbreviation Genotype 
Plp/CreERT:Fgfr2fl/fl 
Vehicle (sunflower 
oil + ethanol) 
Control Homozygous 
Plp/CreERT:Fgfr2fl/fl Tamoxifen Fgfr2ind-/- Homozygous 
Plp/Cre-ve:Fgfr2fl/fl Tamoxifen - Heterozygous 
 
 
3.1.3 Kits 
Kit Manufacturer Art. No. Method 
DirectPCR Lysis 
Reagent (Tail) Peqlab, Erlangen, Germany 31-121-T DNA isolation 
BCA Protein 
Assay Kit 
Pierce® Thermo Scientific, 
IL, USA 
23225 
Protein 
quantification 
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iTaqTM Universal 
SYBR® Green 
qPCR Master Mix 
Bio-Rad, CA, USA 172-5124 PCR 
SuperSignal® 
West Pico 
Chemiluminescent 
substrate 
Thermo Scientific, Il, USA 34077 Western Blot 
AceGlowTM 
Ultrasensitive 
Chemiluminescent 
substrate 
PEQLAB, Erlangen, 
Germany 
37-3420 Western Blot 
 
 
3.1.4 Primers 
Gene (Primer) 5’   to   3’   Sequence 
Fgfr2 lox 
Forward                                    CTAGGCCAGCTGGACCAGAC 
Reverse                                     CATCTTCTCGGTGTTGGTCC 
PLP Cre PCR 
PLP transgene forward            GCGGTCTGGCAGTAAAAACTATC 
PLP transgene reverse             GTGAAACAGCATTGCTGTCACTT 
Cre Internal primer forward     CTAGGCCACAGAATTGAAAGATCT 
Cre Internal primer reverse      GTAGGTGGAAATTCTAGCATCATCC 
 
 
3.1.5 Primary Antibodies 
Name Host Reactivity Mol. W. Tech. Art. No. Manufacturer 
Anti-
pStat1 
Rabbit H, M, R 84/91 kDa WB 9171s 
Cell Signaling Tech, 
MA, USA 
Anti-Stat1 Rabbit 
H, M, R, 
MK 
84/91 kDa WB 9172 
Cell Signaling Tech, 
MA, USA 
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Anti-
CNPase 
Mouse H, M, R 46/48 kDa WB ab6319 Abcam, UK 
Anti-MBP Mouse H, M, R, G 33 kDa WB ab62631 Abcam, UK 
Anti-PLP Rabbit H, M 26/30 kDa WB ab28486 Abcam, UK 
Anti-pERK 
p-44/42 
Rabbit 
H M R Hm 
Mk 
44, 42 WB 4370s 
Cell Signaling Tech, 
MA, USA 
Anti-ERK 
1/2 
Rabbit 
H, M, R, 
MK 
42/44 kDa WB 9102 
Cell Signaling Tech, 
MA, USA 
Anti-AKT Rabbit 
H, M, R, 
MK 
60 kDa WB 9272 
Cell Signaling Tech, 
MA, USA 
Anti-pAKT 
(Ser473) 
Rabbit 
H, M, R, 
MK 
60 kDa WB 4060s 
Cell Signaling Tech, 
MA, USA 
Anti-Flg 
(C-15) 
(FGFR1) 
Rabbit H, M, R 110 kDa WB sc-121 
Santa Cruz Biotech, 
CA, USA 
Anti-Bek 
(C-17) 
(FGFR2) 
Rabbit H, M, R 120 kDa WB sc-122 
Santa Cruz Biotech, 
CA, USA 
Anti-
GAPDH 
Mouse 
Ca, H, M, 
R 
38 kDa WB MAB374 
Chemicon/ 
Millipore, CA; USA 
Anti-Trk B 
(794):sc12 
Rabbit H, M, R 145 kDa WB sc-12 
Santa Cruz Biotech, 
CA, USA 
Anti-BDNF Rabbit H, M, R 17, 13 kD WB sc-546 
Santa Cruz Biotech, 
CA, USA 
Anti 
pFGFR1 
Rabbit H M, R ~145 kDa WB 06-1433 Millipore, CA; USA 
Mac 3 
Clone 
M3/84 
Rat M staining IHC 553322 Pharmingen, USA 
B220 clone 
RA3-6B2 
Rat H, M staining IHC 557390 Pharmingen, USA 
CD3, clone 
CD3-12 
Rat M staining IHC 
MCA 
1477 
Serotec, UK 
Olig-2 Rabbit M staining IHC 18953 IBL, Japan 
Nogo A 
H300 
Rabbit H, M staining IHC Sc 25660 
Santa cruz Biotech, 
CA, USA 
MBP Rabbit M, R staining IHC 62301 Dako, Germany 
SMI 32 Mouse H, M.  staining IHC SMI32 SMI 
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3.1.6 Secondary Anibodies 
Antibody Host Art. No. Manufacturer 
Anti-Rabbit-HRP Goat sc-2004 Santa Cruz Biotech, CA, USA 
Anti-Mouse-HRP Donkey sc-2318 Santa Cruz Biotech, CA, USA 
 
 
3.1.7 PCR Ladders 
Marker Manufacturer 
PageRulerTM Plus Prestained Protein 
Ladder 
Fermentas, Invitrogen, Carlsbad, USA 
Fluorescent Long Range DNA Ladder Jena Bioscience, Jena, Germany 
 
 
3.1.8 Chemicals and Solutions 
Compound Manufacturer 
10x PBS for cell culture (DPBS) Lonza, Köln, Germany 
2-Mercaptoethanol Sigma-Aldrich, Steinheim, Germany  
2-Propanol Sigma-Aldrich, Steinheim, Germany 
3% Hydrogen peroxide Carl Roth, Karlsruhe, Germany 
Acetic acid Merck, Darmstadt, Germany 
Agarose Bioline GmbH, Luckenwalde, Germany 
Ammonium Persulphate (APS) Carl Roth, Karlsruhe, Germany 
Bovine Serum Albumin (BSA) Merck, Darmstadt, Germany 
Bromophenol Blue Neolab, Heidelberg, Germany 
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Citric acid Merck, Darmstadt, Germany 
complete Freund´s adjuvant Sigma, Steinheim, Germany 
Destilled water (Ecostrain®) Braun, Melsungen, Germany 
Dimethylsulfoxide (DMSO) Carl Roth, Karlsruhe, Germany 
Disodium-hydrogen-phosphate  Merck, Darmstadt, Germany 
DNase Qiagen, Hilden, Germany 
EDTA Carl Roth, Karlsruhe, Germany 
Eosin Merck, Darmstadt, Germany 
Eosin Carl Roth, Karlsruhe, Germany 
Ethanol 100% Sigma-Aldrich, Steinheim, Germany 
FBS PAA Laboratories, Pasching, Austria 
Glycerol Carl Roth, Karlsruhe, Germany 
Glycin Merck, Darmstadt, Germany 
Glyzerin Carl Roth, Karlsruhe, Germany 
Hematoxylin Carl Roth, Karlsruhe, Germany 
Isopropanol Merck, Darmstadt, Germany 
Ketamine 
Inersa Arzneimittel GmbH, Freiberg, 
Germany 
Luxol-Fast-Blue Sigma-Aldrich, Steinheim, Germany 
Magnesiumsulfate (MgSO4) Sigma Aldrich, Tachfkirchen, Germany 
Methanol Merck, Darmstadt, Germany 
MOG35-55 Charité Berlin, Berlin, Germany 
Mycobacterium tuberculosis Difco Microbiology, Michigan, USA 
NP40 US Biologicals, MA, Germany 
Paraformaldehyde (PFA) Sigma Aldrich, Taufkirchen, Germany 
Pertussis Toxin Calbiochem, Darmstadt, Germany 
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Ply L Lysine Sigma-Aldrich, Steinheim, Germany 
Potassium chloride (KCL) Merck, Darmstadt, Germany 
Potassiumdihydrogenphosphate  Merck, Darmstadt, Germany 
Protease Inhibitor cocktail Roche, Manheim, Germany 
Proteinase K Sigma-Aldrich, Missouri, USA 
RNAse free water Millipore corporation, MA, USA 
Rotiphorese Gel (30% acrylamide mix) Carl Roth, Karlsruhe, Germany 
Sodium chloride (NaCl) Carl Roth, Karlsruhe, Germany 
Sodium-dihydrogen-phosphate  Merck, Darmstadt, Germany 
Sodium hydrogen carbonate (NaHCO3) Merck, Darmstadt, Germany 
Sodiumdodecylsulfate (SDS) Neolab, Heidelberg, Germany 
Soiumazid (NaN3) Merck, Darmstadt, Germany 
Sunflower oil Sigma-Aldrich, Steinheim, Germany 
Tamoxifen Sigma-Aldrich, Steinheim, Germany 
TEMED Carl Roth, Karlsruhe, Germany 
Tris HCl Carl Roth, Karlsruhe, Germany 
Tris.acetat-EDTA buffer (TAE) 10x Carl Roth, Karlsruhe, Germany 
Trishdroxymethyl aminomethan (Tris) Carl Roth, Karlsruhe, Germany 
Tryphanblue Carl Roth, Karlsruhe, Germany 
Trypsin (2.5g/l) Gibco, Invitrogen, Carlsbad, USA 
Tween 20 Merck, Darmstadt, Germany 
Xylazin 2% 
CEVA Tiergesunheit GmbH, Düsseldorf, 
Germany 
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3.1.9 Consumables 
Consumables Manufacturer 
Cell scrapper GreinerBioOne, Frickenhausen, Germany 
Cellstar® 125 cm2 Cell cultur flasks GreinerBioOne, Frickenhausen, Germany 
Cellstar® 6 Well and 24 well Cell Culture 
Plate 
GreinerBioOne, Frickenhausen, Germany 
Cellstar® 75 cm2 Cell cultur flasks GreinerBioOne, Frickenhausen, Germany 
Cellstar® Flat bottom with Lid, TC-
Plate, 96 well, sterile 
GreinerBioOne, Frickenhausen, Germany 
Cellstar® Plastikpipettes (5 ml, 10 ml) GreinerBioOne, Frickenhausen, Germany 
Cellstar® U-shape with Lid, TC-Plate, 96 
well, sterile 
GreinerBioOne, Frickenhausen, Germany 
Cryobox 136x136x130 mm Ratiolab GmbH, Dreieich, Germany 
Cryo TubeTM vials (1,8 mL; 4,5 mL) Sarstedt AG & Co, Nümbrecht, Germany 
DPX Mountant Sigma Aldrich, Taufkirchen, Germany 
Eppendorf tubes 1,5 mL, 2mL 
Eppendorf Vertrieb Deutschland GmbH, 
Wesseling-Berzdorf, Germany 
Eppendorf tubes 1,5 mL, 2mL (PCR 
clean- pyrogen & DNase free) 
Nerbe Plus GmbH, Winsen (Luhe), 
Germany 
Falcon® Plastic pipettes 10ml, 5ml Becton Dickinson, Heidelberg, Germany 
Falcon tubes (15ml, 50ml) Becton Dickinson, Heidelberg, Germany 
Glass Pasteur pipettes 150 mm Brand, Wertheim, Germany 
Glasswares (different sorts) Fisherbrand; IDL; Schott&Gen; Simax 
Butterfly needle 
DKS LOVERSAN INDUSTRIA 
BIOMEDICA SPA, Gemonio, Italy 
Ministart single use filter (0,2 μm, 0,45 
μm) 
Sartorius Stedim Biotech GmbH, Göttingen, 
Germany 
Nitra-Tex® powder free gloves B. Braun Melsungen AG, Germany 
Nitrocellulose membrane 
GE Healthcare, AmershamTM Hybond ECL, 
Buckinghamshire, UK 
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Parafilm Pechiney Plastic packaging, Menasha, WI 
PCR Tube, cap-strips Applied Biosystems, Darmstadt, Germany 
Pipette tips without filter (10 μL, 100 μL, 
1000 μL) 
Sarstedt AG & Co, Nümbrecht, Germany 
Sterile PCR- clean pyrogen & DNase free 
with filter (10, 100, 200, 1000µl) 
Nerbe Plus GmbH, Winsen (Luhe), 
Germany 
Syringe 25ml for BSA  B. Braun Melsungen AG, Germany 
Tissue culture dishes sterile 35,0 /10mm GreinerBioOne, Frickenhausen, Germany 
 
 
3.1.10 Instruments 
Instrument Manufacturer 
Arpege 75, Liquid nitrogen tank  
Air Liquide Medical GmbH, Düsseldorf, 
Germany  
Axioplan 2 Fluorescence Microscope Carl Zeiss, Jena, Germany 
BEP 2000 Advance (ELISA-Reader)  
Dade Behring Marburg GmbH, Marburg, 
Germany 
Centrifuge type 2-6 Easia shaker 
Medgenix diagnostics 
Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany 
Centrifuge Universal 32 R  Hettich GmbH, Kirchlengen, Germany 
ELISA-Reader Multiscan EX 
Thermo electron corporation, Langenselbold, 
Germany 
Fusion FX7 chemiluminescence system 
Peqlab Biotechnologie GmbH, Erlangen, 
Germany  
Hettich centrifuge (cooling) Hettich GmbH, Kirchlengen, Germany 
Light Microscope for cell culture 
Carl Zeiss Microscopy GmbH, Oberkochen 
Germany 
Magnetic stirrer IKA Werke GmbH, Staufen, Germany 
Nalgene Cryo 1°C Freezing container  Nalgene®, Germany 
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Nanophotometer Implen GmbH, München, Germany 
Neubauer improved cell chamber Brand, Wertheim, Germany 
Neubauer improved Haemocytometer Brand, Wertheim, Germany 
Nuaire Biological Safety Cabinets 
Class II type A/B3 (Sterilbank) 
INTEGRA Biosciences GmbH, Fernwald, 
Germany 
pH-Meter Mettler Toledo GmbH, Giessen, Germany 
Pipette boy 
INTEGRA Biosciences GmbH, Fernwald, 
Germany 
Power pack Peqlab Biotechnologie GmbH, Germany  
Refrigerators and freezers Different companies 
Rotamax 120 (Shaker) 
Heidolph Instruments GmbH & Co. KG,   
Schwabach, Germany  
Sanyo Incu-safe incubator for cell 
culture 
Ewald Innovationstechnik GmbH, Bad 
Nenndorf, Germany 
SmartSpecTM Plus Spectrophotometer BioRad, München, Germany 
StepOne® Real-Time PCR system  Applied Biosystems, Darmstadt, Germany 
Surgical instruments Various companies 
Table top centrifuge EBA 20 Hettich GmbH, Kirchlengen, Germany 
Table top centrifuge micro 120 Hettich GmbH, Kirchlengen, Germany 
TissueRuptor 
Qiagen Instruments, Hombrechtikon, 
Switzerland 
Thermomixer® comfort Eppendorf, Hamburg, Germany  
Trans-Blot® SD Semi-dry transfer cell BIO RAD, München, Germany  
Trans-Blot® SD Semi-dry transfer cell BioRad, München, Germany 
Vortexer vortex-Genie2 
Heidolph Instruments GmbH & Co. KG,   
Schwabach, Germany  
Water bath Memmert GmbH + Co.KG, Germany 
Weighing balance 
Sartorius Stedim Biotech GmbH, Göttingen, 
Germany 
Western blotting system BioRad, München, Germany 
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3.1.11 Buffers  
Buffer Components Volume 
Lysis Buffer (250ml) 
pH 7.4 
NaCl   
Tris  
EDTA  
Glycerol   
NP40  
NaN3 
2.19 g 
0.61 g 
0.07 g 
25 ml 
2.5 ml 
0.025 g 
10% Ammonium Persulfate 
(APS) 
APS 
ddH2O 
1 g 
10 ml 
10% Sodiumdodecylsulfate 
(SDS) 
SDS 
ddH2O 
1 g 
10 ml 
10x PBS (1 Liter) 
pH 7.4 
137 mM NaCl   
2 mM KH2PO4 
2.7 mM KCl  
10 mM Na2HPO4  
H2O 
80 g 
2.4 g 
2 g 
14.4 g 
1000 ml 
6x SDS-PAGE Loading Buffer  
60 mM Tris-HCl (pH 6.8) 
2% SDS  
0.01% Bromophenol blue  
10% Glycerol  
ddH2O  
β-Mercaptoethanol 
36 ml 
60 ml 
60 mg 
60 ml 
144 ml 
65 µl/ml  
10x Trypsin EDTA 
10x Trypsin 
ddH2O 
5 ml 
45 ml 
SDS-PAGE Transfer buffer  
(1 Liter) 
10x Running buffer  
Methanol  
ddH2O 
100 ml 
200 ml 
700 ml 
Blocking buffer (5% BSA)  
Bovine Serum Albumin 
BSA fraction V  
TBST 
5 g 
100 ml 
10x TBS (1 Liter) 
pH 7.2 to 7.6 
Tris   
NaCl  
H2O 
24.2 g 
87.7 g 
1000 ml 
1x TBS-Tween (TBST)  
(1 Liter) 
1x TBS  
0.1% Tween®20   
100 ml 
1 ml 
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3.1.12 Software 
Software Company 
Fusion BioID software Peqlab, Erlangen, Germany 
Graph Pad Prism Software Version 5.01 GraphPad Software, Inc. CA, USA 
Image J software 
Image J 1.47d, National Institute of Health, 
USA 
Microsoft Office Professional 2013 Microsoft corporation, USA 
TierBase Client 4Dm v11 
University of Heidelberg,  Heidelberg, 
Germany 
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3.2 Methods 
3.2.1 Mice 
The Fgfr2flox/flox mouse was received from Michael Sendtner’s laboratory, Würzburg which 
was generated on C57BL/6J background (Blak et al., 2007) and crossbred with B6.Cg-
Tg(Plp1-cre/ERT)3Pop/J to generate inducible oligodendrocyte Fgfr2 conditional knock-
out mice. Mice were bread and grown in JLU-central animal facility, Frankfurter Strasse 
110, Giessen, Germany. All animal experiments were carried out in JLU central animal 
facility and analyzed in the Neurochemical laboratory, Department of Neurology, Giessen, 
Germany. 
3.2.2 Mice Genomic DNA preparation 
The tail pieces (3 mm) and/or ear marks of 3 week old mice were collected under 
anesthesia. The tissue was suspended in Eppendorf tube with 200 µl DirectPCR lysis 
reagent containing freshly prepared Proteinase K (0.2-0.4 µg/µl, Sigma-Aldrich, St. Louis, 
USA). It was incubated in rotating thermomixer (Thermomixer® comfort, Eppendorf, 
Hamburg, Germany) at 55 °C with 400 RPM for 5-10 hours (until no tissue clumps were 
observed). Proteinase K was inactivated by incubating the lysates at 85 °C for 45 minutes. 
The tissue debris and hair were precipitated by centrifuging the lysate for 30 seconds and 
the crude lysate was stored in -20 °C. The lysates were amplified with PCR for Fgfr2lox 
and Plpcre locus confirmation and were subjected to agarose gel electrophoresis.  
 
3.2.3 PCR Protocol 
To determine the genotype, 1 µl of genomic DNA of each sample was diluted in SYBR 
Green PCR Master Mix along with the target amplification primers (Fgfr2 or PLP/Cre 
primers) (Table 3). The PCR thermal profile for each genetic locus was established and 
standardized (Table 4). The PCR products were run and separated in 1.5% agarose gel 
electrophoresis in 120 V for 50 min (BioRad electrophoresis chamber). The bands were 
detected using Fusion Fx7 chemiluminescence system (PEQLAB, Erlangen, Germany). 
The database recording, breeding and documentation of animal experiments was 
managed using TierBase program (University of Heidelberg, Heidelberg, Germany). 
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Table 3. PCR Master Mix (for each sample) 
Fgfr2 Locus PLP Cre Locus 
10 µl   SYBR Green master mix 10 µl   SYBR Green master mix 
1   µl   Forward Primer (Fgfr2) 1   µl   Forward Primer (PLP) 
1   µl   Reverse Primer (Fgfr2) 1   µl   Reverse Primer (PLP) 
1   µl   genomic DNA 1   µl   genomic DNA 
7  µl  H2O 5   µl  H2O 
 1   µl   Forward Primer (CRE) 
1   µl   Reverse Primer (CRE) 
20 µl  TOTAL 20 µl  TOTAL 
 
Table 4. PCR Thermal profile 
 Fgfr2 Locus PLP Cre Locus 
 Temp. Time Cycles Temp. Time Cycles 
Denaturing 95° C 5 min 40 X 95° C 5 min 35 X 
Denaturing 95° C 30 s 95° C 30 s 
Annealing 62.5° C 30 s 51° C 1 min 
Elongation 72° C 45 s 72° C 1 min 
 72° C 2 min 
 
3.2.4 Fgfr2 conditional knockout Induction 
The conditional oligodendrocyte specific Fgfr2 knock out (referred to as Fgfr2ind-/-) was 
induced at 4-5 week old female Plpcre+: Fgfr2flox/flox littermates by 5 consecutive daily 
intraperitoneal Tamoxifen injections (1 mg of Tamoxifen in 100 µl sunflower oil/ethanol) 
(Sigma-Aldrich, Steinheim, Germany). The control littermates were injected with the same 
solution excluding Tamoxifen and received the same treatments in time and place. The 
spinal cord and hippocampus were taken 2 weeks after Tamoxifen administration and 
Fgfr2 expression was analyzed to confirm the knockout efficiency. Animal experiments 
were approved by the local state authorities of Hesse, Giessen, Germany (GI 20/23-Nr. 
31/2008) (Figure 8). 
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3.2.5 Induction and evaluation of MOG35-55-induced EAE   
At 12-13 weeks the oligodendrocyte Fgfr2ind-/- and control mice were anesthetized with 
isoflurane (20-40 seconds) prior to EAE immunization. This was achieved by 4 flank 
subcutaneous injections (300 µg in total) of myelin oligodendrocyte glycoprotein peptide 
(MOG35-55; MOG peptide amino acids - MEVGWYRSPFSRVVHLYRNGK; Charité 
Hospital, Berlin, Germany) emulsified in complete Freund´s adjuvant (Sigma, Steinheim, 
Germany) containing 10 mg Mycobacterium tuberculosis (Difco, Michigan, USA). 
Intraperitoneal pertussis toxin (Calbiochem, Darmstadt, Germany) was administered on 
days 0 and 2 post immunization (300 ng/mouse). Mice were blindly evaluated for the 
clinical course of EAE (up to day 25 daily and later every other day) according to a 5-
scale score criteria; 0 to 5: 0 = normal, 0.5 = distal tail weakness, 1 = complete tail 
weakness, 1.5 = mild hind limb weakness, 2 = ascending hind limb weakness, 2.5 = 
severe hind limb weakness, 3 = hind limb paralysis, 3.5 = hind limb paralysis and 
moderate forelimb weakness, 4 = hind limb paralysis and severe forelimb weakness, 4.5 
= tetraplegia and incontinence, to 5 = moribund/death. Mice were sacrificed and tissues 
were collected in the acute (on day 18-20 p.i.) and chronic phase of EAE (day 60-65 p.i.) 
(Figure 8). 
 
 
Figure 9. Experimental design of the knock out and the KO-EAE study. In the Knock 
out study the OLs Fgfr2 conditional KO was induced in 4-5 week old female mice by 5 
consecutive IP Tamoxifen injections. In the first set of studies the OLs specific Fgfr2 knock 
out downstream signalling was investigated by sacrificing ( † ) the mice 2 weeks after 
Tamoxifen induction.  Different CNS region tissues were collected and subjected to the 
protein analysis. In the KO-EAE study, the Fgfr2ind-/- and control mice were immunized by 
MOG35-55-EAE in 12-13 weeks of age. Here the mice were sacrificed at acute (week 15) and 
chronic (week 20) of immunization and the CNS tissues were collected to investigate protein 
biochemistry as well as histopathology and immunohistochemistry of EAE. 
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3.2.6 Glatiramer acetate (GA) treatment in MOG35-55-induced EAE   
The MOG35-55-EAE immunized Fgfr2ind-/- and control mice (described in the previous 
paragraph) have received a prevention regimen of GA (COPAXONE® 20 mg/ml, Teva 
Pharmaceutical Industries). GA was administered with 8 consecutive daily subcutaneous 
injections, starting on the immunization day. The clinical score of EAE was blindly 
assessed until day 30 when the mice were perfused and the tissues were collected for 
histological studies (Figure 9).  
 
3.2.7 Protein extraction 
In each study (oligodendrocyte Fgfr2 knock out downstream signaling as well as acute 
and chronic EAE) the mice were sacrificed by CO2 inhalation at the termination criteria of 
the respective experiments (described above). The tissues from different CNS regions 
(spinal cord, hippocampus, cortex, cerebellum, and brain stem) were collected carefully 
and immediately kept in 4 °C protein lysis buffer (150 mM NaCl, 20 mM Tris HCl, 1 mM 
EDTA, 10% glycerol, 1% NP40, 0.01% sodium azide).The tissues were homogenized in 
lysis buffer with Tissue rupture (Qiagen Instruments, Hombrechtikon, Switzerland) and 
the tissue debris were precipitated by centrifuging in 4 °C for 20 minutes at 14000 rpm. 
The supernatant was collected and the protein content was measured using BCA assay 
according to manufacturer instructions (Pierce® BCA Protein Assay Kit, Thermo 
Scientific, IL, USA). In brief 25 µl of 1:10 diluted protein samples were poured into 96 well 
flat bottom plate in 3 replicates. 200 µl of Reaction Reagent was added to each well and 
after mixing thoroughly, incubated for 30 minutes at 37 °C. The absorbance was 
Figure 10. Experimental design of GA treatment study. The prevention regimen of GA 
was administered to the Fgfr2ind-/- and control mice on the day of MOG35-55-EAE 
immunization. The mice were treated with 8 daily doses of GA (2 mg in 100 µl per injection) 
and the clinical course of the disease was monitored until the day of euthanization (day 30). 
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measured at 540 nm in room temperature with an ELISA reader. The protein level was 
normalized to 2 µg/µl concentration in lysis buffer and stored at -20° C until it was used 
for SDS-PAGE western blot protein analysis.  
 
3.2.8 Western Blot (WB) Analysis 
The loading buffer (200 mM Tris-Cl (pH 6.8), 400 mM DTT, 8% SDS, 0.4% bromophenol 
blue, and 40% glycerol) was added to the normalized protein lysate (2 µg/µl 
concentration) and was incubated at 95 °C for 5 minutes to achieve protein denaturation. 
Samples were loaded (30 µl of protein lysate, 60 µg protein) on 10% SDS-PAGE 
(Rotiphorese® Gel 30, 10x SDS-PAGE, Carl Roth Gmbh, Karlsruhe, Germany) and ran 
until the target protein bands were separated. Using semidry unit (Trans Blot, Semi dry 
Transfer cell, BioRad) the proteins were transferred to a nitrocellulose membrane (GE 
Healthcare, AmershamTM Hybond ECL, Buckinghamshire, UK) and were blocked with 
5% BSA (diluted in 1x TBST buffer) for 1 hour. The membranes were incubated overnight 
at 4 °C with standardized dilution of each primary antibody in 1x TBST-BSA 5% solution. 
The membranes were washed (3X) with 1XTBST for 5 min each. The secondary antibody 
was administered for 1 hr and washed 3 times with TBST. The membranes were 
developed using SuperSignal West Pico chemiluminescent substrate (Thermo, Pierce 
Biotechnology, Rockford, IL, USA) and AceGlow chemiluminescence Substrate 
(PEQLAB, Erlangen, Germany) in Fusion Fx7 chemiluminescence system (PEQLAB, 
Erlangen, Germany). Finally, the membrane was incubated with GAPDH (1:5000, Merck 
Millipore, Massachusetts, USA) as loading control. The captured proteins signals were 
analyzed using Fusion Bio1D software (PEQLAB, Erlangen, Germany).   
 
3.2.9 Mice Perfusion 
To obtain a rapid and uniform fixation of tissues in order to preserve them in a life-like 
state for further histological and immunohistochemical analysis, the paraformaldehyde 
perfusion via vascular system was chosen. The Fgfr2ind-/- and control mice in acute and 
chronic EAE were anesthetized by intraperitoneal injection of Ketamine (Inersa 
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Arzneimittel GmbH, Freiberg, Germany) and Xylazine (CEVA Tiergesundheit GmbH, 
Düsseldorf, Germany) prior to transcardial perfusion with 4% paraformaldehyde. The 
depth of anesthesia was confirmed with pinch-response method. Following standard 
surgical procedures the abdominal cavity was exposed and the diaphragm was opened 
to reach thoracic cavity. While holding the heart steady with a pair of small forceps (it 
should be still beating), a butterfly needle (DKS LOVERSAN INDUSTRIA BIOMEDICA 
SPA, Gemonio, Italy) (gauge 21) was inserted directly into protrusion of left ventricle with 
care to not penetrate the cardiac septum. A cut made quickly in the right atrium with sharp 
scissors to insure the free flow of the solutions and blood drain (Figure 10). The valve 
was released to allow slow and steady flow of around 20 ml/min of saline solution (1X 
PBS). As soon as the out-flow solution turned clear and liver color changed to pale-
yellow  the flow was switched to 4% paraformaldehyde solution (Sigma Aldrich, 
Taufkirchen, Germany).  Continuous perfusion carried on for about 5-10 min until the tail 
and the four limbs of the mouse become stiff. The brain, spinal cord, spleen, and liver 
were dissected and placed in the 4% paraformaldehyde solution overnight. The following 
day the tissues were fixed in paraffin blocks and slides were cut by microtome for 
histopathological and immunohistochemical analysis. 
 
 
 
 
 
 
 
 
 Figure 11. The schematic view of heart during perfusion. The location of 
butterfly needle insertion into the left ventricle protrusion and the in the right 
atrium cut during perfusion are showed. 
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3.2.10 Hematoxylin and Eosin (H&E) staining  
Hematoxylin and eosin stainings of spinal cord in acute and chronic EAE were performed 
to determine the inflammation. The 1 µm thick slides of spinal cord were kept in 35 ˚C 
overnight and deparaffinized by suspending in xylene. Slides were passed through 
several changes of alcohol to remove xylene and rinsed with water. The rehydrated slides 
were then stained with hematoxylin (a nuclear stain, blue to violet), differentiated (remove 
excess background) with 2 deeps of HCL/EtOH and rinsed under tap water for weak 
alkaline solution treatment existing in the tap water. Here eosin (pink to red) counterstain 
was applied, slides were rinsed and dehydrated, cleared and mounted with coverslip 
(Figure 11).  
 
3.2.11 Luxol fast blue/periodic acid-Schiff stain (LFB/PAS) 
The LFB/PAS stainings of spinal cord in acute and chronic EAE were performed to 
determine the demyelination rate. The 1 µm thick slides of spinal cord were kept in 35 ˚C 
overnight and deparaffinized by suspending in xylene. Slides were passed through 
several changes of alcohol to remove xylene and incubated in a tightly sealed container 
of luxol fast blue at 56°C overnight. The following day the slides went through 95% ethanol 
Figure 12. The schematic procedure of Hematoxylin and Eosin (H&E) staining 
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change to remove excess stain. Slides went through a brief differentiation with lithium 
carbonate solution, rinsed with 70% ethanol and ethanol washed away by distilled water. 
The slides could be either counter stained (myelin is blue and background colorless) or 
followed up with PAS staining. In the latter case, the slides were exposed to 1% periodic 
acid solution for 5 min and rinsed with tap water. Exposed sections to Schiff’s reagent for 
20 min and washed in running tap water for 5 min. They were counterstained with 
hematoxylin for approx. 2 min and differentiated (if necessary), dehydrated, cleared and 
mounted with coverslip (Figure 12). 
 
 
Figure 13. The schematic procedure Luxol fast blue/periodic acid-Schiff stain 
(LFB/PAS) 
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3.2.12 Bielschowsky’s silver staining    
The Bielschowsky’s silver staining of spinal cord in acute and chronic EAE were 
performed to determine the axonal density. In principal the nerve fibers are sensitized 
with a silver solution and when the sections are treated with ammoniacal silver they are 
reduced to a visible metallic silver. The slides were kept overnight in 35 ˚C and 
deparaffinized and rehydrated. Sections were incubated in 20% silver nitrate (AgNO3 
diluted in DH2O) for about 20 mins until they become light brown color (thicker sections 
may look dark brown). The silver nitrate was poured in a conical flask and concentrated 
ammonium hydroxide (32% Ammonia) was added drop by drop (meanwhile preserve 
slides with H2O). The precipitate forms at first an ugly brown and we continue adding 
ammonium hydroxide until its color turns just clear (add 2 drops extra). This solution was 
poured back to the slides and incubated for 15 minutes in 40˚C in dark (or until sections 
become dark brown). The slides were placed directly (without washing) in developer 
working solution for about 1 minute or less (the incubation time is determined depending 
on the reaction intensity after checking under microscope). The reaction was stopped with 
distilled water and slides were incubated in 2% sodium thiosulfate and washed briefly 
under tap water. Finally the slides were dehydrated, cleared and mounted the coverslips.  
 
3.2.13 Immunohistochemistry (IHC)    
The immunohistochemistry of spinal cord in acute and chronic EAE were performed to 
analyze protein expression and localization in the context of tissue morphology through 
specific antibody binding. IHC technique exploits the specific binding of an antibody to its 
target epitope in combination with a chromogenic or fluorescent readout. The 
deparaffinized spinal cord sections were rehydrated and the antigens were retrieved by 
boiling the sections in the appropriate buffer (CD3, Mac-3, B220, MBP and NogoA in 
citrate buffer; Olig2 in TE buffer) (10 mM, pH 6). The endogenous peroxidases were 
blocked with 3% hydrogen peroxidase for 30 min and was followed by 10% FCS blocking 
for 1 hr. The overnight incubation with primary antibodies for macrophages/activated 
microglia (Mac 3, clone M3/84, 1:200, Pharmingen, San Diego, CA, USA), activated B 
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cells (B220, clone RA3-6B2, 1:200, Pharmingen, San Diego, CA, USA), T cells (CD3, 
clone CD3-12, 1:150, Serotec, Oxford, UK), Myelin Basic Protein (MBP, A0623, 1:1000; 
Dako), Olig2(+) and Nogo-A(+) oligodendrocyte (Olig 2, 1:300, IBL, Gunma, Japan; Nogo-
A(+), 1:50, Santa Cruz Biotechnology, CA, USA) were  performed in 4°C. Next day the 
sections were incubated with biotinylated secondary antibodies (goat anti-rat; Mac 3, 
B220 and goat anti-rabbit; CD3, MBP, Olig2, Nogo-A) and signals were detected with 
avidin-biotin complex by DAB. To determine the cells, a brief nucleus stain with 
hematoxylin was performed (Figure 13). Images were captured on a digital camera 
(Olympus DP71, Olympus America Inc., Center Valley PA, USA) using a light microscope 
(Olympus BX51, Hamburg, Germany). The demyelination of MBP(+) area was analyzed 
using Image J software (ImageJ 1.47d, National Institute of Health, USA). The axonal 
density was counted with a 25-point-grid ocular at 1000x magnification (oil immersion). 
CD3(+), B220(+), Mac3(+), Olig2(+), and Nogo-A(+)  cells were counted at 400x 
magnification with an ocular morphometric grid. 
 
 
Figure 14. The schematic procedure of Immunohistochemistry 
 
   Methods 
 
51 
 
3.2.14 Statistical analysis 
All analysis were performed genotype blinded and no samples were excluded from the 
analysis. The appropriate statistical analyses were chosen for each experiment. The EAE 
clinical score (three independent experiments were included for each acute and chronic 
EAE) differences between the genotypes and histological data analysis were performed 
using Mann-Whitney U test. Other experiments were analysed using unpaired T-test (The 
statistical significance was set at P ≤ 0.05). Statistical analysis and graph preparations 
were achieved using GraphPad Prism 6.0 software for windows (GraphPad Software, 
San Diego, California, USA) and the values are expressed as mean ± standard error of 
mean. The magnitude of P values were resembled with stars: * P < 0.05, **P < 0.005, 
***P < 0.001. 
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4 RESULTS 
  
4.1 Oligodendrocyte specific Fgfr2 knockout study 
4.1.1 Genotype confirmation 
The Fgfr2 complete knockout mice die at E10.5 due to defects in the placenta. Selective 
disruption of the FGFR2b isoform causes severe impairment in the development, 
resulting in lethality immediately after birth. Disruption of the FGFR2c isoform, although 
not lethal, results in impairment in skull and bone development (Eswarakumar et al., 
2005). Hence, we used Cre-Lox system of DNA modification to target Fgfr2 gene in 
oligodendrocytes after mice CNS development. As explained in the methods, the Fgfr2 
floxed mice was crossed with transgenic Cre expressing (under PLP promoter which is 
specific for oligodendrocytes) mice. The genotype of mice was confirmed with PCR, using 
PLP Cre and Fgfr2 loxP primers (Figure 14). No effects of mortality, body weight or other 
phenotype changes were observed in oligodendrocyte specific Fgfr2 conditional knockout 
mice. 
Figure 15. Genotyping. To determine and select the appropriate genotype, mice tail 
lysates were amplified by PCR, Fgfr2 lox (A) and PLP Cre locus (B) were confirmed. 
PCR amplified products were separated with agarose gel electrophoresis. The 
representative agarose gel images are shown. (-ve control: wild type). 
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4.1.2 Oligodendrocyte specific Fgfr2 knockout confirmation 
The efficacy of oligodendrocyte specific Fgfr2 Tamoxifen inducible Cre mediated deletion 
was confirmed by western blot analysis in 6 week old female mice (2 weeks after 
Tamoxifen induction). The expression levels of the heavy splicing variant of FGFR2 (120 
kDa) was significantly downregulated in spinal cord (p = 0.013) and brain rest (p = 0.028). 
There was no regulation in hippocampus and cortex in the heavy splicing variant of 
FGFR2. The expression level of FGFR2 light chain (110 kDa) was significantly 
downregulated in spinal cord (p = 0.001) and brain rest (p ≤ 0.001). However, there was 
no significant regulation in hippocampus and cortex of Fgfr2ind-/- mice. This finding indicate 
that the conditional oligodendrocytes FGFR2 downregulation is dependent on the 
oligodendrocytes population and therefore, it is only significantly downregulated in the 
oligodendrocytes rich regions of CNS (spinal cord and total brain lysates) (Figure 15, 16). 
 
4.1.3 Oligodendrocyte specific Fgfr2 knockout does not affect FGFR1 regulation 
To investigate whether Fgfr2 knockout induction will lead to FGFR1 regulation as a 
compensatory mechanism, the protein lysates were evaluated for FGFR1 expression 
using WB analysis. The protein analysis of different brain regions (spinal cord, 
Hippocampus, cortex, and brain rest) in Fgfr2ind-/- mice and controls after knockout 
induction showed no statistically significant regulation in FGFR1 protein (Figure 17). 
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Figure 16. Fgfr2 expression in Fgfr2ind-/- mice in spinal cord and 
hippocampus. To determine the knockout efficacy of OL Fgfr2 Tamoxifen 
inducible mice, the different CNS lysates were evaluated by WB analysis. (A) 
Spinal cord. Fgfr2 was downregulated in the heavy (120 kDa) and the light (110 
kDa) splicing variants of Fgfr2ind-/- mice (p = 0.013, p = 0.001). (B) Hippocampus. 
Both splicing variants of Fgfr2 were downregulated in hippocampus after 
Tamoxifen induction, however, the regulations were not statistically significant (p 
= 0.497, p = 0. 063). Values are expressed as mean ± SEM (n = 3). 
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Figure 17. Fgfr2 expression in Fgfr2ind-/- mice in cortex and brain rest. To 
determine the KO efficacy of OL Fgfr2 Tamoxifen inducible mice, the different CNS 
lysates were analyzed by WB. (A) Cortex. Neither of the Fgfr2 splicing variants 
were regulated in cortex after Tamoxifen induction (p = 0.972, p = 0.085). (B) Brain 
rest. Fgfr2 was downregulated in the heavy and the light chains of Fgfr2ind-/- mice 
(p = 0.028, p ≤ 0.001). Values are expressed as mean ± SEM (n = 3). 
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Figure 18. Fgfr1 expression in Fgfr2ind-/- mice. (A) The representative protein 
bands of Fgfr1 expressed in Fgfr2ind-/- mice and controls in different CNS regions. 
(B) The statistical analysis of Fgfr1 expression levels showed no significant 
regulation of heavy splicing variant of Fgfr1 (140 kDa) in spinal cord (p = 0.547), 
hippocampus (p = 0.269), cortex (p = 0.802), and brain rest (p = 0.436). Fgfr1 light 
splicing variant (110 kDa) evaluation also showed no significant regulation in spinal 
cord (p = 0.450), hippocampus (p = 0.440), cortex (p = 0.502), and brain rest (p = 
0.362). Values are expressed as mean ± SEM (n = 3). 
A 
B 
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4.1.4 Characterization of oligodendrocyte specific FGFR2 downstream signaling 
FGFR2 triggers a series of critical and complex protein downstream signaling. We studied 
the expression and regulation pattern of FGFR2 downstream signaling pathways involved 
in the inflammatory response as well as neuronal growth and development. The WB 
protein analysis of different brain regions (spinal cord, Hippocampus, cortex, and brain 
rest) in Fgfr2ind-/- mice and its controls were investigated 2 weeks after oligodendrocytes 
knockout induction.  
 
4.1.4.1 Oligodendrocyte Fgfr2 ablation effect on AKT phosphorylation 
To analyze the influence of oligodendrocyte specific Fgfr2 on AKT phosphorylation, whole 
protein lysates of cortex, spinal cord, hippocampus and brain rest from control and 
Fgfr2ind-/- were analyzed by western blot. AKT, a serine/threonine kinase, is one of the 
major FGFR2 mediators which regulates a variety of cellular functions by phosphorylating 
numerous downstream mediators in a cell specific manner. AKT pathway participate in 
various critical biological functions such as cell proliferation and survival by 
phosphorylating a variety of substrates. The WB analysis of pAKT expression showed 
higher phosphorylation level in Fgfr2ind-/- mice in spinal cord (p ≤ 0.001), hippocampus (p 
= 0.023), cortex (p = 0.002), and brain rest (p = 0.005) (Figure 20). 
 
4.1.4.2 Oligodendrocyte Fgfr2 ablation effect on ERK1/2 phosphorylation 
ERK1 (44 kDa) and ERK2 (42 kDa) are related protein-serine/threonine kinases that 
participate in the Ras-Raf-MEK-ERK signal transduction cascade. They regulate a wide 
range of processes including cell adhesion, cell cycle progression, cell migration, cell 
survival, differentiation, metabolism, proliferation, and transcription. The WB analysis of 
pERK expression levels showed no significant regulation of pERK1 (44 kDa) in spinal 
cord (p = 0.859), hippocampus (p = 0.269), cortex (p = 0.296), and brain rest (p = 0.743). 
The evaluation of pERK2 (42 kDa) showed downregulation in spinal cord (p = 0.012), 
hippocampus (p = 0.009), cortex (p = 0.035), and brain rest (p = 0.008) (Figure 21).  
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Figure 19. AKT phosphorylation in Fgfr2ind-/- mice. (A) The representative 
protein bands of pAKT expressed in Fgfr2ind-/- mice and controls in different CNS 
regions. (B) The statistical analysis of pAKT expression showed higher 
phosphorylation level in Fgfr2ind-/- mice in spinal cord (p ≤ 0.001), hippocampus (p 
= 0.023), cortex (p = 0.002), and brain rest (p = 0.005).  
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Figure 20. ERK phosphorylation in Fgfr2ind-/- mice. (A) The representative 
protein bands of pERK expressed in Fgfr2ind-/- mice and controls in different CNS 
regions. (B) The statistical analysis of pERK expression levels showed no 
significant regulation of heavy splicing variant of pERK (44 kDa) in spinal cord (p 
= 0.859), hippocampus (p = 0.269), cortex (p = 0.296), and brain rest (p = 0.743). 
The evaluation of pERK light chain (42 kDa) showed downregulation in spinal cord 
(p = 0.012), hippocampus (p = 0.009), cortex (p = 0.035), and brain rest (p = 0.008). 
Values are expressed as mean ± SEM (n = 3).  
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Figure 21. TrkB expression in Fgfr2ind-/- mice. The representative protein bands 
of TrkB expressed in Fgfr2ind-/- mice and controls in different CNS regions. (B) The 
statistical analysis of TrkB expression levels showed no significant regulation of 
heavy splicing variant of TrkB (145 kDa). The evaluation of TrkB light chain (95 
kDa) showed downregulation in spinal cord (p = 0.011), hippocampus (p = 0.090), 
cortex (p = 0.031), and brain rest (p = 0.005). Values are expressed as mean ± 
SEM (n = 3).  
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4.1.4.3 The effect of oligodendrocytes Fgfr2 ablation on other downstream   
             mediators   
The expression pattern of various other FGFR2 downstream signalling protein mediators, 
potentially involved in the inflammatory response and neuronal growth and development 
were investigated from different CNS regions using WB analysis. The expression level of 
Stat1/2, DCLK, BDNF, CREB, P38, PCNA, and MBP proteins showed no statically 
significant regulation in Fgfr2ind-/- mice when compared to controls (n=3). 
 
4.1.5 TrkB is downregulated upon Fgfr2 knockout induction 
To analyze the influence of oligodendrocyte specific FGFR2 on TrkB expression, whole 
protein lysates of cortex, spinal cord, hippocampus and brain rest from control and 
Fgfr2ind-/- mice were analyzed by western blot. The heavy splicing variant of TrkB (145 
kDa) was not detected in spinal cord and hippocampus protein lysates and it was not 
regulated in cortex and brain rest. The light chain of TrkB (95 kDa) was downregulated in 
spinal cord (p = 0.011), cortex (p = 0.031), and brain rest (p = 0.005) in Fgfr2ind-/- mice but 
not in hippocampus (p = 0.090) (Figure 21).  
 
4.1.6 The Fgfr2 ablation does not affect the oligodendrocyte population 
FGF receptors are known to play profound roles in neurons and oligodendrocyte 
proliferation, migration and maturation as well as central nervous system myelination. 
Here we investigated the effect of oligodendrocytes specific Fgfr2 conditional knockout 
on oligodendrocyte cell population in Fgfr2ind-/- and controls. Therefore, the Olig2(+) and 
NogoA(+) cells in spinal cord were quantified by immunohistochemistry. These analyses 
indicate the population of oligodendrocyte progenitors (Olig2(+)) or mature 
oligodendrocytes (NogoA(+)) were not altered in Fgfr2ind-/- when compared to WT controls 
(Figure 22). 
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Figure 22. Immunohistochemistry of oligodendrocyte populations in 8 week old 
mice. The number of Olig2(+) (A, B, and C) and NogoA(+) (D, E, and F) oligodendrocytes 
in spinal cord cross-sections in controls and Fgfr2ind-/- mice 2 weeks after knockout 
induction. The representative spinal cord sections are shown. The number of OLs was 
not altered due to Fgfr2 deletion. Values are expressed as mean ± SEM (n = 4). 
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4.2 EAE in Fgfr2ind-/- mice 
4.2.1 EAE clinical score 
The Fgfr2ind-/- and control mice were immunized with MOG35-55 peptide and were 
monitored for their EAE clinical symptoms (Figure 23). The EAE scores were evaluated 
as described in methods (section 3.2.5).  
 
 
 
Figure 23. Clinical symptoms of MOG35-55 peptide induced EAE in Fgfr2ind-/- mice. 
Healthy mice showed with active tail while walking (A), spiral tail around the rod (E), and 
hanging on 4 limbs on the net (I). The slightly affected mice with complete tail weakness 
(clinical score 0.5-1.0) are showed while walking, standing on the rod and hanging on the 
net (B, F, J). The mice with ascending to severe hind limb weakness (clinical score 1.5-2.5) 
are shown (C, G, K). The last column shows the representative figures of mice with hind 
limb paralysis and forelimb weakness (clinical score 3-4) (D, H, and L). 
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4.2.2 Fgfr2ind-/- mice show a milder EAE disease course 
The disease course of MOG35-55-induced EAE was investigated in the acute and chronic 
phases of EAE (Figure 24). At 11-12 weeks of age, EAE was induced in female Fgfr2ind-
/- and their control littermates (n=13) in a total of 3 independent experiments. The onset 
of disease was on day 9 p.i. in both study groups. On days 16 and 19 p.i. the EAE score 
was significantly reduced in Fgfr2ind-/- (p = 0.036, p = 0.042). From days 24 until day 60 
(with the exception of day 45) Fgfr2ind-/- mice displayed a milder course of EAE compared 
to controls (p < 0.05). At the chronic phase of EAE, Fgfr2ind-/- mice had a mild paraparesis 
whereas controls suffered from a severe paraparesis. Body weight did not differ between 
the two groups. Fgfr2 gene deletion in oligodendrocytes did not increase mortality.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Clinical course of EAE. The onset of symptoms was not different 
between Fgfr2ind-/- mice and controls. The EAE score was decreased on days 16 and 
19 in Fgfr2ind-/- mice. From day 24 to day 60 (with the exception of day 45) Fgfr2ind-
/- mice displayed a milder course of EAE. In this phase Fgfr2ind-/- mice presented with 
a mild paraparesis whereas controls still had a moderate paraparesis. (* indicate p 
< 0.05, ** indicate p < 0.01) n= 13, data are presented as mean ± SEM 
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4.2.3 The inflammatory index is lower in Fgfr2ind-/- mice in chronic EAE 
In alignment with the clinical course of EAE, the histological differences between Fgfr2ind-
/- mice and controls were more evident in the chronic EAE. The inflammatory index was 
investigated in spinal cord white matter of acute and chronic EAE using H & E staining. 
There was no significant difference between the 2 groups in the acute EAE (p = 0.675), 
however, the infiltration rate was 33% less in Fgfr2ind-/- mice in chronic EAE (p = 0.002) 
(Figure 25).   
4.2.4 The myelin loss is less in Fgfr2ind-/- mice in chronic EAE 
The susceptibility of Fgfr2ind-/- mice to demyelination and MBP loss in spinal cord white 
matter were investigated using LFB/PAS and MBP staining respectively. The 
demyelination rate did not differ in acute EAE (p = 0.132), however, it was 43% lower 
Fgfr2ind-/- mice in chronic EAE (p = 0.002) (Figure 26). MBP staining showed a higher 
preservation of myelin (63%) in Fgfr2ind-/- mice only in chronic EAE (p = 0.016) (Fig. 27). 
4.2.5 The nerve fibers are better preserved in Fgfr2ind-/- mice in chronic EAE 
The axonal density was investigated with Bielschowsky's Silver Staining in spinal cord 
white matter of acute and chronic EAE. The analysis showed no statistically significant 
difference between the 2 groups in the acute phase of the disease (p = 0.119). In the 
chronic EAE the axonal density in Fgfr2ind-/- mice was 46% higher than controls (p = 0.001) 
(Figure 28). 
 Table 5. Histopathological analysis of EAE spinal cord 
 
Pathology Acute p-value Chronic p-value 
Control Fgfr2ind-/- Control Fgfr2ind-/- 
Inflammatory 
Index 
4.70 ± 
0.33 
3.67 ± 
0.48 
0.133 3.98 ± 
0.22 
2.66 ± 
0.24 
0.004 
Demyelination 
(%) 
24.60 ± 
1.39 
18.26 ± 
3.37 
0.132 37.20 ±  
2.81 
21.00 ±  
2.12 
0.002 
Myelin expression 
(%) 
10.03 ± 
0.45 
8.62 ±   
1.82 
0.484 9.76 ± 
1.54 
3.53 ±   
0.33 
0.016 
Axonal density 
(%) 
41.65 ± 
1.17 
45.65 ± 
1.85 
0.119 34.14 ±  
1.87 
49.86 ±  
2.47 
0.001 
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Figure 25. The inflammatory index of EAE was investigated with H & E staining 
in the spinal cord sections of acute (A, B, and C) and chronic (D, E, and F) phases 
of the disease. The representative spinal cord sections are shown. The inflammatory 
index (C and F) was less in Fgfr2ind-/- mice in the chronic EAE. n = 4, data are 
presented as mean + SEM 
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Figure 26. The demyelination of EAE was investigated with LFB/PAS staining 
in the spinal cord sections of acute (A, B, and C) and chronic (D, E, and F) phases 
of the disease. The representative spinal cord sections are shown. The 
demyelination rate (C and F) was less in Fgfr2ind-/- mice only in the chronic EAE. n = 
4, data are presented as mean + SEM 
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Figure 27. The demyelination of EAE was investigated with MBP 
immunostaining in the spinal cord sections of acute (A, B, and C) and chronic (D, 
E, and F) phases of the disease. The representative spinal cord sections are shown. 
The demyelination rate (C and F) was less in Fgfr2ind-/- mice only in the chronic EAE. 
n = 4, data are presented as mean + SEM 
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Figure 28. The axonal density of EAE was investigated with Bielschowsky's 
Silver Staining in the spinal cord sections of acute (A, B, and C) and chronic (D, E, 
and F) phases of the disease. The representative spinal cord sections are shown. 
The axonal density (C and F) was higher in Fgfr2ind-/- mice only in the chronic EAE. 
n = 4, data are presented as mean + SEM  
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4.2.6 Altered composition of the inflammatory infiltrate in Fgfr2ind-/- mice 
Immunohistochemical analysis were performed to further investigate the composition of 
infiltrates in spinal cord EAE lesions. Histological studies addressing inflammatory index 
(H&E staining) determined a lower immune infiltration as well as demyelination (LFB/PAS 
staining) in Fgfr2ind-/- mice. Immunostaining for CD3(+), B220(+) and Mac3(+) cells were 
performed and quantified to achieve specific illustration of cellular infiltrate composition in 
spinal cord white matter lesions. The number of CD3(+) T cells were not affected by Fgfr2 
deletion in acute EAE (p = 0.578) however, it was significantly lower in chronic stage in 
Fgfr2ind-/- mice (p = 0.002)   (Figure 29). In the acute phase of EAE Mac3(+) cells (p = 
0.045) and B220(+) B cells (p = 0.002) were reduced in Fgfr2ind-/- mice. In the chronic 
phase of EAE Mac3(+) cells (p = 0.007) and B220(+) B cells (p = 0.005) were reduced in 
Fgfr2ind-/- (Figure 30 and 31). 
 
4.2.7 The oligodendrocytes population is not affected after EAE immunization  
To investigate whether the changes in demyelination we observed between Fgfr2ind-/- and 
controls was caused by altered oligodendrocyte populations we quantified Olig2(+) cells 
and NogoA(+) cells in spinal cord sections by immunohistochemistry. Quantifications of 
Olig2(+) showed no difference between Fgfr2ind-/- and controls in either the acute (p = 
0.590) or chronic phase of EAE (p = 0.203) (Figure 32). Fgfr2 deletion did not affect 
NogoA(+) cells (mature oligodendrocytes) in the acute (p = 0.386) or chronic phase of 
EAE (p = 0.251) (Figure 33). 
 
Table 6. Immune cell infiltration analysis of EAE spinal cord 
 
Pathology Acute p-value Chronic p-value 
Control Fgfr2ind-/- Control Fgfr2ind-/- 
CD3 (+)  
T cells 
380 ± 55 336 ± 53 0.578 235 ± 24 124 ± 11 0.002 
Mac3 (+) 
Macrophages 
666 ± 95 398 ± 46 0.045 298 ± 17 180 ± 15 0.007 
B220 (+) 
B cells 
241 ± 15 149 ± 10 0.002 93 ± 10 47 ± 7 0.005 
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Figure 29. The T cell infiltration in white matter lesions was investigated by 
CD3(+) immunostaining of spinal cord cross-sections in Fgfr2ind-/- and control mice. 
The representative spinal cord sections of acute (A, B, and C) and chronic (D, E, and 
F) EAE are shown. The T cell infiltration (C and F) was reduced in Fgfr2ind-/- mice 
only in the chronic EAE. n = 4, data are presented as mean + SEM  
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Figure 30. The macrophages/microglia infiltration in white matter lesions was 
investigated by Mac3(+) immunostaining of spinal cord cross-sections in Fgfr2ind-/- 
and control mice. The representative spinal cord sections of acute (A, B, and C) and 
chronic (D, E, and F) EAE are shown. The macrophage infiltration (C and F) was 
lower in Fgfr2ind-/- mice in the acute and chronic EAE. n = 4, data are presented as 
mean + SEM  
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Figure 31. B cell infiltration in white matter lesions was investigated by B220 
immunostaining of spinal cord cross-sections in Fgfr2ind-/- and control mice. The 
representative spinal cord sections of acute (A, B, and C) and chronic (D, E, and F) 
EAE are shown. The macrophage infiltration (C and F) was lower in Fgfr2ind-/- mice 
in the acute and chronic EAE. n = 4, data are presented as mean + SEM  
 
   Results 
 
74 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32. Immunohistochemistry of oligodendrocyte progenitor cells in white 
matter lesions was investigated by Olig2 immunostaining of spinal cord cross-
sections in Fgfr2ind-/- and control mice. The representative spinal cord sections of 
acute (A, B, and C) and chronic (D, E, and F) EAE are shown. The oligodendrocyte 
number did not alter in acute or chronic EAE in Fgfr2ind-/- when compared with 
controls. n = 4, data are presented as mean + SEM  
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Figure 33. Immunohistochemistry of mature oligodendrocyte population in 
white matter lesions was investigated by NogoA immunostaining of spinal cord 
cross-sections in Fgfr2ind-/- and control mice. The representative spinal cord sections 
of acute (A, B, and C) and chronic (D, E, and F) EAE are shown. The mature 
oligodendrocyte number did not alter in acute or chronic EAE in Fgfr2ind-/- when 
compared with controls. n = 4, data are presented as mean + SEM  
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4.2.8 Fgfr2 deletion modulates ERK and AKT phosphorylation and TrkB Expression 
To characterize the underlying mechanisms of oligodendrocyte Fgfr2 deletion in EAE, 
FGFR2-dependent downstream signaling was investigated in the spinal cord and 
hippocampus in both the acute phase (day 18-20) and chronic phase (day 60-65) of EAE 
(Figure 34, 35). Western blot analysis of FGFR2 in spinal cord and hippocampus showed 
no regulation in acute EAE (p = 0.961, p = 0.842), however, it was significantly reduced 
in chronic stage of the disease in spinal cord protein lysate (p = 0.001) (Figure 35 A). It 
appears that ablation of FGFR2 leads to upregulation of TrkB in both acute and chronic 
phase of EAE, however, it is statistically significant only in chronic EAE in hippocampus 
(p = 0.028) (Figure 35 D). 
 The phosphorylated form of AKT was upregulated in Fgfr2ind-/- mice in acute 
hippocampus (p = 0.002) (Figure 34 F) and in chronic spinal cord (p = 0.014) (Figure 35 
E). The level of ERK phosphorylation was downregulated in the chronic spinal cord and 
hippocampus, however, it was statistically significant only in spinal cord (p ≤ 0.031) (figure 
35 G).  
We also confirmed that the expression levels of Stat1, Stat3, IkB, P38, BDNF, CREB, 
DCLK and PCNA proteins were not significantly regulated in any stages of EAE.   
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Figure 34. FGFR2 downstream signaling in Fgfr2ind-/- in the acute EAE. (A, B) The 
expression level of FGFR2 was not regulated in spinal cord and hippocampus 
in Fgfr2ind-/- mice when compared to controls. (C, D) The expression level of pAKT 
in Fgfr2ind-/- was upregulated in spinal cord and hippocampus, however, it was 
statistically significant only in hippocampus. (E, F) The pERK expression in Fgfr2ind-
/- was not regulated. (G, H) The protein expression of TrkB in Fgfr2ind-/- mice was 
upregulated only in hippocampus. Values are expressed as mean ± SEM (n = 5). 
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Figure 35. FGFR2 downstream signaling in Fgfr2ind-/- in the chronic EAE. (A, 
B) The expression level of FGFR2 was regulated only in the spinal cord of Fgfr2ind-
/- when compared to controls. (C, D) The expression level of pAKT in Fgfr2ind-/- was 
upregulated in spinal cord but not in hippocampus. (E, F) The pERK expression 
in Fgfr2ind-/- was downregulated in both spinal cord and hippocampus. (G, H) The 
TrkB expression in Fgfr2ind-/- was upregulated in both spinal cord and hippocampus, 
however, it was statistically significant only in hippocampus. Values are expressed 
as mean ± SEM (n = 3). 
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Figure 36. FGFR2 expression in chronic EAE. To determine the FGFR2 
expression pattern due to EAE immunization, the non-EAE groups of control and 
Fgfr2ind-/- mice were included.  (A) Spinal cord. FGFR2 was upregulated in the 
control and Fgfr2ind-/- mice when compared to the respective EAE immunized 
groups (p = 0.026, p = 0.021). In both EAE and non-EAE groups the Fgfr2ind-/- mice 
expressed a lower level of FGFR2 (p = 0.039, p = 0.001). (B) Hippocampus. 
FGFR2 was upregulated in the control and Fgfr2ind-/- mice when compared to the 
respective EAE immunized groups, however, it was statistically significant only in 
the control group (p = 0.001, p = 0.16). Fgfr2 was not regulated within EAE and 
non-EAE groups. Values are expressed as mean ± SEM. 
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Figure 37. pAKT expression in chronic EAE. To determine the pAKT expression 
pattern due to EAE immunization, the non-EAE groups of control and Fgfr2ind-/- 
mice were included. (A) Spinal cord. pAKT was upregulated in Fgfr2ind-/-  mice 
when compared to the respective EAE immunized Fgfr2ind-/- mice (p = 0.003). In 
EAE group the expression of pAKT was upregulated in Fgfr2ind-/- mice (p = 0.014). 
(B) Hippocampus. pAKT was upregulated in the control and Fgfr2ind-/- mice when 
compared to the respective EAE immunized groups (p = 0.007, p = 0.036). pAKT 
was not regulated in Fgfr2ind-/- mice within the EAE or non-EAE groups when 
compared to their respective controls. Values are expressed as mean ± SEM. 
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Figure 38. pERK expression in chronic EAE. To determine the pERK expression 
pattern due to EAE immunization, the non-EAE groups of control and Fgfr2ind-/- 
mice were included. (A) Spinal cord. pERK was upregulated in the control and 
Fgfr2ind-/- mice when compared to the respective EAE immunized groups (p = 
0.014, p = 0.029). In EAE group the Fgfr2ind-/- mice expressed a lower level of pERK 
(p = 0.031). (B) Hippocampus. pERK was not regulated in the control and Fgfr2ind-
/- mice when compared to the respective EAE immunized mice (p = 0.809, p = 
0.256). pERK was downregulated in Fgfr2ind-/- mice within EAE and non-EAE 
groups, however, it was not statistically significant (p = 0.758, p = 0.204). Values 
are expressed as mean ± SEM. 
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Figure 39. TrkB expression in chronic EAE. To determine the TrkB expression 
pattern due to EAE immunization, the non-EAE groups of control and Fgfr2ind-/- 
mice were included. (A) Spinal cord. TrkB was downregulated in the control but 
not Fgfr2ind-/- mice when compared to the respective EAE immunized groups (p = 
0.004, p = 0.088). In EAE group the Fgfr2ind-/- mice expressed a higher level of 
TrkB, however, it was not statistically significant (p = 0.274). (B) Hippocampus. 
TrkB was downregulated in the control and Fgfr2ind-/- mice when compared to the 
respective EAE immunized mice (p = 0.015, p = 0.032). TrkB was upregulated in 
Fgfr2ind-/- mice within EAE immunized group (p = 0.033). Values are expressed as 
mean ± SEM. 
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4.3 Glatiramer acetate treatment  
Treated with GA, the Fgfr2ind-/- mice exhibited a milder course of EAE 
To characterize the potential association of FGFR2 with anti-inflammatory and 
neuroprotective effects of glatiramer acetate in MOG35-55-induced EAE, the Fgfr2ind-/- and 
control mice were treated with GA pretreatment regimen. GA is one of the well-known 
immunomodulatory drugs currently used to treat multiple sclerosis. Although the 
immunomodulatory effects of GA are not quite understood, they are mainly attributed to 
its capacity in stimulating specific Th2/3 cells which enter CNS and express IL-10 and 
TGF- β as well as neurotrophic factors such as BDNF the ligand of TrkB which is 
upregulated in Fgfr2ind-/- mice. The blind-assessed clinical score of EAE shows that GA 
prevention regimen delays the EAE manifestation in both knockout and controls (3-4 
days) but significantly reduces the disease severity only in Fgfr2ind-/- mice (Figure 36).  
 
 
 
 
 
 
 
 
Figure 40. Pretreatment regimen of GA in MOG35-55-induced EAE.  
The onset of symptoms was not delayed in Fgfr2ind-/- mice when compared to 
controls. The disease peak was significantly lower in the in Fgfr2ind-/- mice in acute 
EAE and the difference was retained through the chronic phase of EAE. The clinical 
score was assessed genotype-blinded. n = 3, data are presented as mean + SEM. 
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5 DISCUSSION 
Identifying and interrupting the key regulatory signalling mechanisms involved in 
demyelination are of great importance in treating demyelinating diseases such as multiple 
sclerosis. FGF/FGFR interactions are complex and regulate diverse functions of 
oligodendrocyte lineage cells, the myelin producing cells in the CNS (Furusho et al., 
2015). Present study aims at better understanding the FGF/FGFR2 interactions in vivo, 
utilizing an oligodendrocyte specific Fgfr2 conditional knockout mice. To characterize the 
role of oligodendroglial FGFR2 in demyelinating conditions, the clinical course of MOG35-
55-EAE was investigated in Fgfr2ind-/- mice. Contrary to our hypothesis we observed a 
milder disease course of MOG35-55-EAE in Fgfr2ind-/- mice. The pathological analysis 
showed decreased lymphocyte and microphage/microglia infiltration in spinal cord. The 
degree of demyelination was lower in Fgfr2ind-/- mice and axons were better preserved 
while the oligodendrocyte progenitor cells and mature oligodendrocyte populations did 
not alter. In Fgfr2ind-/- mice TrkB expression and AKT phosphorylation were upregulated 
while ERK phosphorylation was reduced.   
 
5.1 Fgfr2ind-/- mice have normal phenotype  
FGF/FGFR interactions exert various physiological effects including cellular proliferation, 
migration, differentiation, and survival (Furusho et al., 2011). The complete Fgfr2 
depletion leads to embryonic lethality at E10.5 due to defects in the placenta while the 
selective disruption of the FGFR2b isoform causes severe impairment in the development 
of the lung, limbs and other tissues resulting in lethality immediately after birth. Fgfr2 
mutations that enhance receptor activity cause abnormal fusions of the bones within the 
skull and limbs in Apert, Crouzon, Jackson-Weiss and Pfeiffer syndromes (Eswarakumar 
et al., 2005, Beenken and Mohammadi, 2009). Moreover, FGFR2 has been proven to 
play an important role in breast cancer development, being essential for induction of self-
renewal and cell maintenance of human breast tumour initiating cells (Czaplinska et al., 
2014). Therefore and to avoid developmental or other functional complications, we 
utilized a Tamoxifen inducible Cre mediated approach to delete Fgfr2 in oligodendrocyte 
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lineage cells. Our investigation on Fgfr2ind-/- mice revealed that the conditional deletion of 
Fgfr2 under PLP promoter does not result in any behavioural or phenotypical changes in 
Fgfr2ind-/- mice when compared to its C57BL/6J background controls. 
  
5.2 FGFR2 signaling pathway  
5.2.1 FGFR2 is downregulated in the white matter regions of Fgfr2ind-/- mice  
In vitro FGFR2 is highly expressed by mature oligodendrocytes (not progenitors) 
coincidentally with major myelin proteins and its ligand binding leads to enhanced growth 
of oligodendrocyte processes and the formation of myelin-like membranes (Fortin et al., 
2005). In vivo FGFR2 is expressed by oligodendrocytes in myelinated fibre tracts of adult 
rodent brain, spinal cord, and optic nerve and is present in purified myelin, however, its 
expression is low or not expressed in neurons and astrocytes (Fortin et al., 2005, Bansal 
et al., 2003). In our study the whole protein lysates showed downregulation of FGFR2 in 
spinal cord, and brain rest in Fgfr2ind-/- mice (but not in cortex and hippocampus). Since 
this conditional knockout system targets oligodendrocytes specifically, it could draw the 
speculation that CNS white matter regions composite a higher proportion of 
oligodendrocytes. Hence, the white matter rich regions of Fgfr2ind-/- mice appear to receive 
stronger influence by Tamoxifen induction, leading to significant FGFR2 downregulation.  
 
5.2.2 FGFR1 is not compensated due to oligodendroglial Fgfr2 knockout 
FGF family members insert their various impacts in CNS mainly through FGFR1 and 
FGFR2 receptors. Furthermore, FGFR1 and 2 share many common ligands such as FGF-
2 (main ligand for FGFR1) and FGF-10 (main ligand for FGFR2) (Guillemot and Zimmer, 
2011). One of the main processes involved in oligodendrocyte progenitor cell migration 
and maturation is the mitogenic and chemokinetic effects of FGF-2 exerted via FGFR1 
activation. FGF-2 could be involved in oligodendrocyte response during demyelination 
and remyelination, however, the effects exerted by FGF-2 are controversial (Butt and 
Dinsdale, 2005, Clemente et al., 2011). In MS patients FGFR1 expressing 
oligodendrocyte progenitor cell subpopulations are increased in active plaques and 
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chronic inactive peri-plaques where remyelination normally occurs, suggesting an 
ameliorating role for FGF/FGFR1 interaction in MS recovery (Clemente et al., 2011). 
Considering the numbers of ligands that FGFR1 and 2 share and the overlapping 
functions they exert in oligodendrocyte homeostasis and myelination, it is fundamental to 
determine whether oligodendrocyte Fgfr2 knockout could be compensated by FGFR1 
upregulation. Our findings show that the loss of oligodendroglial FGFR2 signalling in vivo 
has no impact on FGFR1 expression in spinal cord and different brain regions.  
 
5.2.3 AKT phosphorylation was upregulated in Fgfr2ind-/- mice  
In this study the whole protein lysate of spinal cord and different brain regions 
(hippocampus, cortex, and brain rest) showed increased AKT phosphorylation in Fgfr2ind-
/- mice. AKT, a serine/threonine kinase and a downstream of FGFR2, regulates a variety 
of cellular functions by phosphorylating numerous downstream mediators in a cell specific 
manner. AKT signalling is known to influence cell survival, proliferation, and differentiation 
(Brazil et al., 2004). Although AKT is often considered to be a key cell survival regulatory 
mediator, in the oligodendrocyte lineage, AKT overexpression appears to have little 
impact on oligodendrocyte cell number (Flores et al., 2008). This is in line with our findings 
which indicate that oligodendroglial FGFR2 ablation induced p-AKT expression, does not 
affect oligodendrocyte progenitor cells or mature oligodendrocyte numbers. Transgenic 
mice with over activation of phosphatidylinositol-3-phosphate kinase (PI3K)/AKT pathway 
display increased myelin thickness (Ishii et al., 2012). Conversely, mTOR inhibition (a 
downstream target of PI3K/AKT), led to attenuation of this increase (Narayanan et al., 
2009).  Enhanced CNS myelination in oligodendroglial overexpressing p-AKT achieved  
with no changes in the proliferation or survival of oligodendrocyte progenitors or mature 
cells (Narayanan et al., 2009). This could suggest that the myelin sheath thickness might 
have altered in Fgfr2ind-/- mice in spite of no significant change in oligodendrocyte 
populations (precursor or mature). In our study western blot analysis of MBP showed no 
regulation in different CNS regions of Fgfr2ind-/- mice, however, we did not generate data 
on the myelin sheath thickness. 
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5.2.4 ERK phosphorylation is downregulated in Fgfr2ind-/- mice 
Our analysis of the whole protein lysates showed that ERK2 but not ERK1 
phosphorylation was decreased in spinal cord and different brain regions (hippocampus, 
cortex, and brain rest) of Fgfr2ind-/- mice.  One of the three major subgroups of MAPKs, 
ERK1/2, play crucial roles in cellular processes including proliferation, stress response, 
apoptosis, and immune response. The signals that lead to ERK activation are usually 
initiated on the cell surface, primarily by various membrane-bound receptors (Liu et al., 
2007). Ligand binding activates the intracellular kinase domain of FGF receptors resulting 
intermolecular transphosphorylation of the tyrosine kinase domains, initiating 
downstream signalling through four major pathways namely RAS/MAPK, PI3K-AKT, JNK 
and STAT (Huang et al., 2015). However, Miraoui’s group brought more attention to 
MAPK signalling in FGFR2 downstream pathway by showing that FGFR2 activation in 
mesenchymal stem cells induces ERK1/2 but not JNK or PI3K/AKT activation (Miraoui et 
al., 2008). Our study downgraded the relevence of the fourth major downstream pathway 
of FGFR2, STAT signalling, since oligodendroglial FGFR2 knockout did not affect STAT 
expression in spinal cord. Further support for our finding in suggesting a positive relation 
between FGFR2 and ERK phosphorylation comes from Schuller’s study. They showed in 
vitro, FGFR2 overexpression increased ERK phosphorylation in MCF-7 (Huang et al., 
2015). Others showed that the gain of function point mutations in FGFR2 enhances 
ERK1/2 phosphorylation in PC12 cells (neuronal precursor-like cells) (Schuller et al., 
2008).   
 
Negative feedbacks regulate FGFR signalling at different levels by receptor internalization 
or induction of negative regulators such as FGFRL1, SEF, and MAPKs. While FGFRL1 
and SEF regulators interrupt ligand binding, MAPK pathway mainly modulates the 
intracellular signalling (Turner and Grose, 2010). In vitro, Ser779 cytoplasmic domains of 
FGFR1 and FGFR2 (but not FGFR3 or 4) is required for the sustained activation of Ras 
and ERK (Lonic et al., 2013). Exogenous human recombinant FGF2 activates 
FGFR/MEK/ERK pathway, which induces cell growth and inhibits apoptosis. Conversely, 
inhibiting FGF receptor, interrupts mesoderm stimulation and angiogenesis  (Hu et al., 
2014). In vitro studies show that blockade of ERK pathway enhances apoptosis in tumour 
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cells (Sakamoto et al., 2013). However, in our study p-ERK2 downregulation in CNS of 
Fgfr2ind-/- mice did not affect the progenitor or mature oligodendrocyte population. A 
possible explanation for this finding could emerge from a work done by Yao’s group. They 
demonstrated that ERK2 cannot compensate for all mediated functions of ERK1 since 
Erk1-deficient mice despite being viable and fertile, have defective thymocyte maturation. 
Yet, in vitro ERK1 can compensate for ERK2 loss (Yao et al., 2003). 
 
5.2.5 TrkB but not BDNF is regulated in Fgfr2ind-/- mice  
Bioactivity of BDNF has been demonstrated in neuronal cultures, with its expression 
enhanced upon stimulation. BDNF and FGF receptor signalling regulate cell migration of 
neuroblasts along rostral migratory steam (Zhou et al., 2015). BDNF belongs to the 
neurotrophin family of growth factors and modulates axonal growth, neuronal activity, and 
activity-dependent synaptic and dendritic plasticity (Hohlfeld et al., 2000, Hohlfeld et al., 
2006). Like FGF receptors the high-affinity receptor for BDNF, TrkB, is also a receptor 
tyrosine kinase. In our study BDNF itself was not regulated, however, its receptor TrkB 
was downregulated in Fgfr2ind-/- mice. This could indirectly affect the functions which are 
attributed to BDNF signaling in the central nervous system. Upon ligand binding, various 
signalling pathways such as mitogen-activated protein kinase, phosphatidylinositol 3-
kinase and Fyn-mediated actin polymerization are stimulated through TrkB receptors 
(Harada et al., 2011). TrkB and FGFR2 share similar and possibly overlapping patterns 
of cellular distribution in inferior colliculus, hippocampus and cerebellum of F344 rats 
(Sato et al., 2001). Application of FGF-2, a major ligand for FGFR1/ 2, up-regulates BDNF 
and TrkB in ganglion cells of frog optic nerve after axotomy (Soto et al., 2006). Earlier 
studies conducted in our group showed TrkB was upregulated in spinal cord of 
oligodendrocyte specific Fgfr1 knockout mice (Rajendran, 2014). However, in contrary, 
oligodendrocyte specific Fgfr2 deletion resulted in TrkB downregulation in spinal cord, 
and brain rest with no regulation of BDNF in Fgfr2ind-/- mice. This suggest TrkB signaling 
and synthesis could have a close association to FGFR2 biogenesis. The discrepancy of 
TrkB regulation associated to each FGFR1 and FGFR2 is not clearly understood and 
needs to be further investigated.     
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5.3 Oligodendroglial Fgfr2 depletion leads to a milder course of EAE   
The current study is the first to investigate and characterize the role of oligodendroglial 
FGFR2 signaling in the course of MOG35–55-EAE. Our data demonstrate that interrupting 
oligodendrocyte specific FGFR2 signaling leads to a milder disease course in chronic 
EAE.  The onset of EAE did not differ between the two groups and during acute EAE, 
although presenting the trend, Fgfr2ind-/- mice did not show a statistically significant milder 
disease course. Various studies in different experimental paradigms have proposed 
contrary roles for FGF signaling in remyelination and clinical recovery. Beneficial roles 
were reported from gene therapy, stating that introducing FGF2 by viral vectors reversed 
the clinical and pathological signs of chronic EAE (Ruffini et al., 2001). Furthermore, 
systemic deletion of FGF2  showed more severe symptoms of EAE, decreased 
remyelination, and increased nerve fiber degeneration (Rottlaender et al., 2011). 
Conversely, others reported mice lacking FGF2 or FGFR1 manifest increased 
oligodendrocyte population and improved remyelination of cuprizone-induced lesions. 
This proposes an inhibitory role for FGF signaling in oligodendrocyte differentiation and 
remyelination. These conflicts partially might be due to the fact that FGF signaling elicits 
various responses in different cell types (Furusho et al., 2015).  
In MS patients FGF2 and FGFR1 are upregulated in oligodendrocyte progenitors in active 
plaques and in chronic inactive peri-plaques, where remyelination normally occurs 
(Clemente et al., 2011). However, it has been unclear whether this upregulation around 
demyelinated lesions is indicative of enhanced or interrupted repair capacity (Furusho et 
al., 2015). Our protein analysis of spinal cord in chronic EAE show that FGFR2 is 
upregulated upon EAE immunization, proposing a negative role for FGFR2 in the course 
of EAE. Therefore, it is legitimate to see Fgfr2ind-/- mice with a lower FGFR2 expression, 
show milder signs of EAE clinical symptoms. Putting together, we conclude a negative 
role for oligodendroglial FGFR2 signaling in the pathology of MOG35–55-EAE. 
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5.4 Reduced immune infiltration in Fgfr2ind-/- mice  
In our study the impaired oligodendroglial FGFR2 signaling which led to milder clinical 
symptoms of MOG35–55-EAE, was associated with decreased spinal cord infiltration of 
macrophages and/or activated microglia as well as B220 (+) B cells in both acute and 
chronic EAE. In addition to progenitor and mature oligodendrocytes, other FGFR 
expressing cells such as reactive astrocytes and microglia, are also likely to be affected 
by modulation of FGF2 in the lesions (Furusho et al., 2015). During induction and peak 
phases of EAE, massive infiltration of peripheral macrophages is seen in acute lesions of 
EAE (Linker and Lee, 2009). In spinal cord of EAE induced mice the activated microglia 
show increased FGF2 and FGFR1 expression (Liu et al., 1998). The elevated capacity of 
activated macrophages into CNS is correlated to pro-inflammatory chemokines and their 
receptors (Jiang et al., 2014). In cuprizone model the production of FGF2 in microglia has 
peaked during demyelination. Conversely, the microglial FGF2 expression was 
downregulated during remyelination (Voß et al., 2012).    
 
In our study the CD3 (+) T cell infiltration was significantly reduced in Fgfr2ind-/- mice only 
in chronic EAE. Autoreactive T cells against myelin proteins play a role in EAE 
development. The Th1 and Th17 infiltrates release a large amount of pro-inflammatory 
cytokines in CNS (IFN-γ, IL-17, IL-12, IL-23) which induce demyelination and neuronal 
death in the inflamed CNS (Jiang et al., 2014). In the later phase of EAE anti-inflammatory 
Th2 and regulatory T cells develop and control inflammation by damping Th1 cell activity 
and pro-inflammatory cytokine release (Unutmaz et al., 2010). There are no data on direct 
association between FGFRs/ FGFR2 and immune infiltration. However, the downstream 
mediators of FGF receptors such as AKT and ERK are known to interfere immune 
response in different interfaces which will be discussed in the following passages. 
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5.5 FGFR2 downstream signaling in MOG35-55-EAE 
 
In this study the underlying mechanisms behind the milder EAE clinical course 
concomitant with reduced immune infiltration, reduced demyelination, and better axonal 
preservation in Fgfr2ind-/- mice could be illustrated from investigating downstream FGFR2 
signaling of spinal cord. Our data demonstrate that in chronic EAE Fgfr2ind-/- mice shows 
increased AKT phosphorylation, reduced ERK phosphorylation and enhanced TrkB 
expression.   
 
 
5.5.1 p-AKT upregulation in Fgfr2ind-/- mice plays an ameliorating role in pathology 
of MOG35-55-EAE 
We demonstrated that the loss of FGFR2 in oligodendrocyte lineage cells lead to 
increased AKT phosphorylation in different CNS regions which is concomitant with a 
milder course of MOG35–55-EAE. AKT signaling is a key regulatory pathway, involved in a 
variety of cellular and biological functions. In vitro AKT/mTOR signaling is imminent  to 
achieve proper differentiation of oligodendrocyte progenitor cells into mature 
oligodendrocytes (Dai et al., 2014). It is also showed that IGF-1 stimulates 
oligodendrocyte progenitor proliferation by sustained AKT phosphorylation (Cui and 
Almazan, 2007). In astrocyte-conditioned media AKT phosphorylation provides trophic 
support for oligodendrocyte progenitors of rat brain  against cellular insults such as 
oxidative stress, starvation, and oxygen-glucose deprivation (Arai and Lo, 2009). In 
contrary, our analysis of spinal cord sections indicate no significant change in precursor 
or mature oligodendrocyte populations of Fgfr2ind-/- mice in acute or chronic EAE. While 
others reported that p-AKT downregulation reduced myelin thickness in mice and AKT 
over-activation resulted in hypermyelination (Fyffe-Maricich et al., 2013). 
 
Our histological and immunohistochemical data demonstrate lower demyelination and 
better preserved axons in Fgfr2ind-/- mice in chronic EAE. Multiple lines of evidence 
support these findings, proposing a positive role for AKT phosphorylation in protecting 
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axons during neurodegenerative conditions. In vitro AKT phosphorylation protected the 
cultured cortical neurons against hypoxia induced neuronal death (Siren et al., 2001). In 
vivo AKT phosphorylation included neuroprotective (Diem et al., 2001), anti-apoptotic 
(Kermer et al., 2000), and pro-survival and pro-functional effects in retinal ganglion cells 
(Sättler et al., 2004). BTBD10, a neuronal cell death suppressor and neuronal growth 
enhancer, improved ALS condition via positive regulation of AKT phosphorylation (Nawa 
et al., 2008). EAE Treatment with arylpiperazine (a neuroprotective compound) contribute 
to the delayed onset, progression, and overall suppression of EAE. These effects are 
exerted by reducing apoptosis of CNS cells via increased activation of anti-apoptotic 
mediator of AKT and its downstream effector kinases (Popovic et al., 2015).  
 
Through immunohistochemical analysis we assessed a decreased number of 
macrophages/activated microglia and B220 (+) B cells in the spinal cord of Fgfr2ind-/- mice 
in both acute and chronic EAE. Furthermore, in Fgfr2ind-/- mice CD3 (+) T cells infiltration 
was significantly reduced in the chronic phase of the disease. These data suggest a 
negative relation between immunomodulatory response and AKT phosphorylation in the 
course of EAE. The further substantiating data in support of this relation comes from an 
AKT3-/- study. These mice were more severely affected by EAE immunization and the 
demyelination was higher in AKT3-/- mice spinal cord lesions in both acute and chronic 
EAE. The mRNA level of proinflammatory cytokines (IL-2, IL-17, and IFN-γ) were higher 
in spinal cords of AKT3-/- mice. Immunohistochemical analysis revealed decreased 
numbers of Foxp3+ regulatory T cells in the spinal cord of AKT3-/- mice. In vitro 
suppression assays showed that AKT3-deficient Th cells are less susceptible to 
regulatory T cell–mediated suppression (Tsiperson et al., 2013). Another study shows 
that RGMa plays a role in Th17-cell-mediated neuronal death by inducing AKT de-
phosphorylation and is involved in both apoptosis and axonal degeneration. (Tanabe and 
Yamashita, 2014). Moreover, AKT phosphorylation is reported to contribute in BBB 
integrity. A selective acetylcholinesterase inhibitor, donepezil, revealed ameliorating 
clinical and pathological parameters in EAE including improved magnetic resonance 
imaging outcomes and reduced permeability of BBB coupled with increasing AKT 
phosphorylation (Jiang et al., 2013). Putting together we conclude an ameliorating role 
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for PI3K/AKT pathway in the pathology of MOG35–55-EAE potentially through providing 
trophic, neuroprotective, and anti-apoptotic support for neurons and enhancing 
oligodendrocyte functionality but not population which leads to improved myelin 
composition. Furthermore, AKT phosphorylation may contribute in attenuating the 
immunomodulatory response and providing support for BBB integrity.     
 
5.5.2 ERK phosphorylation exerts negative immunomodulatory effects in  
         pathology of MOG35-55-EAE 
In our study downregulation of ERK2 phosphorylation in spinal cord was associated with 
the milder clinical course of chronic MOG35–55-EAE in Fgfr2ind-/- mice. In Chronic EAE the 
demyelination was lower in Fgfr2ind-/- mice and axons were better preserved. Different 
studies indicate that the Ras/Raf/MEK/ERK pathways, as a result of activation by various 
growth factors, provide imminent functions in the proliferation, migration, or survival of 
oligodendrocyte progenitor cells (Guardiola-Diaz et al., 2012). However, there are 
contradictions on the role this pathways play in oligodendrocyte progenitor cells and 
mature myelinating oligodendrocytes. Oligodendrocyte progenitor cell differentiation was 
not affected in primary cortical cultures of ERK1-null knockout mice while it was only 
transiently interrupted in ERK2 conditional single knockout mouse brain cultures (Fyffe-
Maricich et al., 2011). In vitro studies (utilizing a panel of stage-specific antigenic markers 
and pharmacological inactivation of ERK1/2) demonstrated that distinct stages in 
oligodendrocyte developmental pathway are differentially regulated by ERK1/2 
phosphorylation. In particular, the progression of the early to late progenitor stage 
requires ERK1/2 activation (Guardiola-Diaz et al., 2012). In the current study the 
immunohistological investigations of chronic MOG35–55-EAE spinal cord sections showed 
p-ERK2 downregulation does not impact progenitor or mature oligodendrocyte number in 
Fgfr2ind-/- mice. 
 
FGFR1/2 contribute to upstream and downstream signalling of ERK1/2 which is crucial 
for oligodendrocyte functions in maintaining the myelin and axonal integrity (Ishii et al., 
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2014). ERK1/2 inhibition in cultured oligodendrocytes result in attenuated extension of 
oligodendrocyte processes. In mice lacking oligodendroglial FGFR1/2 myelin thickness 
was reduced which was accompanied by downregulation of ERK1/2 phosphorylation, 
suggesting a correlation between ERK/MAPK activation and myelin thickness (Furusho 
et al., 2012). However, in mature oligodendrocytes the expression of ERK1 and ERK2 
overlaps, therefore, it is unlikely that single gene deletions will fully interrupt the function 
of ERK1/ERK2 signalling in myelination (Fyffe-Maricich et al., 2011). ERK1-null knockout 
in OPCs and oligodendrocytes coupled with floxed-ERK2 conditional knockout showed in 
the absence of ERK1/2 signalling OPCs were able to complete cell cycle, differentiate, 
and initiate myelination normally. However, they failed to increase myelin thickness in 
proportion to axon calibre in the spinal cord. This suggest late-stage regulatory role for 
ERK1/2 in CNS myelination (Ishii et al., 2012). In our study, the immunohistology of spinal 
cord sections for MBP showed no regulation in myelin expression in Fgfr2ind-/- mice.  
 
A number of investigations including the current study, attribute immunomodulatory roles 
to ERK signaling. Here we discuss the correlation between pERK2 downregulation and 
reduced immune infiltration of T-cells, B-cells, macrophages/ microglia. ERK1 null 
knockout mice showed enhanced susceptibility to myelin MOG35–55-EAE and displayed a 
bias toward Th1 type immune response which reflected by increased INF-γ production by 
MOG-specific T cells and lower IL-5 secretion (Agrawal et al., 2006). In accordance to 
our findings, the combined inhibition of MEK1/2, the kinase upstream of ERK, during or 
after EAE induction reduced the clinical signs of EAE by suppressing dendritic cell IL-23 
and IL-1β production and suppressing autoantigen-specific T cell. ERK activation 
promote Th17 responses in vivo while ERK inhibition suppressed autoantigen-specific 
Th17 and Th1 responses and attenuated EAE (when administered at the induction of 
acute EAE or therapeutically in a relapsing-remitting model). ERK inhibition also 
suppressed IFN- γ as well as IL-17 production (Brereton et al., 2009). ERK activity is 
essential for the process of positive selection, and it differentially affects CD4 and CD8 T 
cell maturation (Fischer et al., 2005). ERK1/2 activation to some extent determines the 
fate of Th1/ Th2 immune cells. Loss of ERK2 severely impedes Th1 differentiation while 
enhances the development of Foxp3+-induced T regulatory cells (Chang et al., 2012).  
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ERK signalling is reported to play profound role in BBB integrity and therefore, mediating 
immune infiltration. In vitro BBB model assessments show microwave radiation 
induces BBB damage by activating the VEGF/Flk-1-ERK pathway, enhancing Tyr 
phosphorylation of occludin (Wang et al., 2014). Moreover, Somatostatin hormone has 
been demonstrated to reduce local and systemic inflammation reactions as well as 
maintaining the integrity of the BBB by decreasing the LPS-induced phosphorylation of 
ERK1/2 (Lei et al., 2014). Dendritic cell recruitment by CNS in MOG35–55-EAE was shown 
to go through CCL2 chemotaxis and paracellular transmigration across the BBB which 
was facilitated by ERK phosphorylation (Sagar et al., 2012).  
 
5.5.3 TrkB signaling may play a Janus-like role in pathology of MOG35-55-EAE 
Our data provide evidence that glial TrkB signaling might play a dual role in pathology of 
EAE. We investigated the expression of TrkB and its activating ligand BDNF, before and 
after EAE immunization in Fgfr2ind-/- mice. Experimental axotomy suggests BDNF is 
promoting neuronal survival, oligodendrocyte proliferation and axonal remyelination 
(Gravel et al., 1997). Moreover, in vitro studies revealed, BDNF and other neurotrophins 
are also produced by human T cells, B cells, and macrophages (Song et al., 2013). BDNF 
is found in cells forming perivascular infiltrates and in the lesions invading cells of acute 
disseminated encephalomyelitis and MS brain autopsy (Stadelmann et al., 2002). BDNF 
synthesis related to inflammatory responses can exert regenerative and protective effects 
during CNS tissue damage (De Santi et al., 2009). However, EAE studies show the 
conditional BDNF gene deletion in T cell lineage, results in reduction of 
neuroinflammation, reduced T cell infiltration and proliferation, and reduction of in vitro 
cytokine release (Ralf Linker, 2007).  
 
In our study BDNF was not significantly regulated but since most, if not all known functions 
of BDNF are exerted through TrkB receptor, we focused on TrkB expression. After EAE 
immunization in a readily TrkB downregulated Fgfr2ind-/- mice (compared to WT controls), 
the TrkB expression further decreases. However, the reduction proportion in Fgfr2ind-/- 
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mice is much lower than controls. In other words TrkB expression reduced in both Fgfr2ind-
/- and controls due to EAE induction but Fgfr2ind-/- mice undergoes less TrkB fluctuations 
(by having a lower level of TrkB at the time of EAE induction and less decrease of TrkB 
expression after EAE immunization). Therefore and considering a milder course of EAE 
in Fgfr2ind-/- mice, it is not possible to attribute a mere negative or positive role for TrkB in 
pathology of EAE. This could explain the source of discrepancy on the described role of 
TrkB and BDNF, reported from different research studies. 
 
 
TrkB is robustly expressed in neurons in immediate vicinity to MS plaques. Observation 
of single neurons with pronounced TrkB-immunoreactivity near MS lesions, suggested 
upregulation of TrkB in a proportion of damaged neurons (Stadelmann et al., 2002). The 
soluble factors released by astrocytes as a result of TrkB signalling induced neuronal 
degeneration and apoptosis (Colombo et al., 2012). While astrocyte specific TrkB 
knockout mice showed a milder course of EAE and were better protected from 
neurodegeneration, BDNF specific depletion in astrocytes showed enhanced disease 
severity associated with axonal loss, suggesting a BDNF-mediated neuroprotective 
mechanism (Linker et al., 2010, Colombo et al., 2012). In MS, TrkB influences the 
susceptibility of activated T cells to apoptosis. These encephalitogenic T cells are 
generally believed to be the initiator of autoimmune inflammatory attack against the 
myelin sheaths and neuronal elements in MS (Zang et al., 1999).  Putting together, we 
conclude the discrepancy of TrkB expression pre and post EAE immunization in Fgfr2ind-
/- mice, which is coupled with a milder course of EAE, might be the result of a Janus-like 
role that TrkB signaling plays in the pathology of EAE. In other words TrkB might escalate 
the immune response initially but promote neuronal protective mechanisms later on 
during chronic EAE.  
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5.6 GA treatment further ameliorates MOG35-55-EAE in Fgfr2ind-/- mice  
Our data demonstrated that GA administration (prevention regimen) delayed and further 
reduced severity of MOG35–55-EAE clinical score in Fgfr2ind-/- mice while these 
ameliorating impacts were more trivial in WT controls. Characterizing of 
neurodegeneration is one of the major objectives in scientific investigations to tackle 
neurological autoimmune disorders. A salient feature in the course of multiple sclerosis is 
oligodendrocyte degeneration followed by myelin and axonal damage. Persuading more 
efficient treatments, combination therapies are emerging as promising approaches in 
targeting neurodegenerative diseases. FGFR2 is known to play profound role in neurons 
and oligodendrocyte proliferation, migration and maturation as well as central nervous 
system myelination. It is demonstrated by our group that FGFR2 could serve as a potent 
target for addressing the pathology of MOG35–55-EAE by interfering immunomodulatory 
pathways induced due to EAE immunization.  On the other hand GA or Copaxone, a 
mixture of synthetic peptides, is one of the potent approved drugs available for MS 
therapy.  Although, not clearly understood, the neuroprotective effects of GA are exerted 
through restoring the impaired neurotrophic factor secretion in CNS and neurogenesis in 
the site of injury. Moreover, it induces the production of secreted IL-1 receptor antagonist, 
sIL-1Ra, which is a natural inhibitor of IL-1β, the essential cytokine for differentiation of 
IL-17-producing T helper cells (Carpintero et al., 2010). The immunomodulatory 
mechanisms of GA are mainly attributed to its capacity in stimulating specific Th2/3 cells 
that cross BBB, accumulate in CNS and express IL-10 and TGF- β as well as neurotrophic 
factors such as BDNF (Aharoni et al., 2008). Using kinase knockdown and specific 
inhibitors, it is demonstrated that GA induces sIL-1Ra (a major compound determining its 
anti-inflammatory effects) production via the activation of PI3Kδ, AKT, MEK1/2, and 
ERK1/2, demonstrating that both PI3Kδ/Akt and MEK/ERK pathways rule sIL-1Ra 
expression in human monocytes (Carpintero et al., 2010). These findings suggest GA 
and FGFR2 signalling might share some neuroprotective and immunomodulatory 
pathways (AKT, ERK pathways) however, in the opposite direction and with the reverse 
outcomes. We conclude the combined therapy approach of inhibiting FGFR2 signalling 
with GA treatment could further delay the onset/progression and overall suppression of 
MOG35–55-EAE.
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6 SUMMARY 
Myelin is a bioactive membrane established by oligodendrocytes during postnatal 
development and is essential for receiving and conducting electrical impulses by axons. 
Myelin acts as a target during many autoimmune neurological conditions such as MS. 
FGF signaling is known to be crucial for development, proliferation and maintenance of 
oligodendrocytes and OPCs, hence, influencing myelination. Yet, the role of FGFR 
signaling in MS and EAE is poorly understood. Hypothesizing MOG35-55-EAE will cause 
more severe symptoms in oligodendroglial Fgfr2 depleted mice, we designed a 
Tamoxifen inducible PLP Cre mediated conditional Fgfr2 knockout in oligodendrocyte 
passage under C57BL/6 background. No phenotypic changes were observed in Fgfr2ind-
/- mice. To our surprise, Fgfr2ind-/- showed a milder disease course of MOG35-55-EAE 
coupled with reduced immune infiltration (T-cells, B-cells, macrophages/ microglia), 
reduced demyelination, less inflammation, and better axonal preservation. Ablation of 
Fgfr2 in oligodendrocytes caused reduced ERK phosphorylation as well as increased 
TrkB expression and AKT phosphorylation. The number of OLs and OPCs were not 
altered in Fgfr2ind-/- mice in EAE induced or non-EAE condition when compared to their 
respective controls. Prevention regimen of GA treatment delayed and further ameliorated 
the MOG35-55-EAE manifestation in Fgfr2ind-/- mice. Taken together, our findings indicate 
a deteriorating role for FGFR2 in the pathology of MOG35-55-EAE by boosting immune 
response through MEK/ERK, PI13/AKT, and TrkB crosstalk and signaling. Therefore, 
FGFR2 and its downstream signaling mediators could serve as effective potential 
treatment prospects in tackling immunological related CNS disorders. 
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ZUSAMMENFASSUNG 
Myelin ist eine Biomembran, die von Oligodendrozyten postnatal gebildet wird. Myelin 
ermöglicht eine schnelle Erregungsleitung elektrischer Impulse. Die Myelinscheiden, die 
Axone umgeben, sind Angriffspunkt bei autoimmun bedingten neurologischen 
Erkrankungen des ZNS wie Multiple Sklerose. Über den FGF Signalweg werden 
Entwicklung und Proliferation von Oligodendrozyten und Oligodendrozyten-
Vorläuferzellen (OPCs) gesteuert. Dieser FGFR Signalweg wurde bislang bei MS und 
dem Tiermodell experimentelle autoimmune Enzephalomyelitis (EAE) kaum 
charakterisiert. Unsere Hypothese war die, dass bei MOG35-55-EAE in Mäusen, deren 
oligodendrozytäres FGFR2 entfernt wurde, EAE schwerer verläuft. Hierfür nutzten wir 
einen durch Tamoxifen induzierbaren PLP Cre vermittelten konditionalen FGFR2 
Knockout (Fgfr2ind-/-). Es wurden keine phänotypischen Veränderungen bei den Fgfr2ind-
/- Mäusen beobachtet. Die Fgfr2ind-/- Mäuse zeigten im Gegensatz zur Hypothese einen 
milderen EAE Krankheitsverlauf, weniger Immuninfiltration (T-Zellen, B-Zellen, 
Makrophagen/Mikroglia), eine geringere Demyelinisierung und besser erhaltene Axone. 
Weiterhin führte die Entfernung von FGFR2 in den Oligodendrozyten zu einer reduzierten 
Phosphorylierung von ERK und einer gesteigerten Expression von TrkB und 
Phosphorylierung von AKT. Die Anzahl der Oligodendrozyten und OPCs änderte sich 
weder bei den Fgfr2ind-/- Mäusen ohne EAE noch im EAE Experiment. Eine frühe 
Behandlung mit Glatiramerazetat milderte Symptome einer EAE bei den  Fgfr2ind-/-
Mäusen ab. Zusammengefasst zeigen unsere Ergebnisse, dass FGFR2 in 
Oligodendrozyten die Pathologie der MOG35-55-EAE durch eine verstärkte 
Immunantwort durch MEK / ERK, PI13 / AKT und TrkB Interaktionen und Signalwege 
negativ beeinflusst. Daher könnten FGFR2 und die nachgeschalteten Signalmediatoren 
mögliche molekulare Behandlungsziele bei immunologisch vermittelten Erkrankungen 
des ZNS sein. 
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